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1.0 A brief history of Multiple Myeloma (MM) 
 
1.1 History of MM: 
 
The understanding of biology and subsequent determination of appropriate treatment 
has seen a paradigm shift in Multiple Myeloma. The first recorded case is well noted 
during the 19th century by Dr Solly where post-mortem examination of a 39-year-old 
female Sarah Newbury revealed multiple bone fractures, bone deformities and 
replacement of marrow with grumous material which did not resemble or contain pus. 
Dr Solly and Mr Birkett of Guy's Hospital further noted that the cells in this grumous 






      
Fig.1: An early drawing of plasma cells(PC): Dalrymple, John. On the 





       
 
 
Fig.2: Sarah Newburry with a) bone deformities and fractures. b) and c) bony 




While a similar case of fragile and brittle bones was being reviewed, by Dr McIntyre, a 
general practitioner at Harley Street, London of Mr McBean; a reputed 44 year old 
grocer experienced polyuria with nocturnal accidents which stiffened his linens with no 
urethral discharge otherwise. Mr McBean passed away three years later and autopsy 
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revealed fragile bones, with bone marrow of a gelatinous consistency. Presenting with 
his symptoms, Dr McIntyre also noted increased specific gravity of urine, 
predominantly attributed to viscous albumin like substance which stiffened the body 
linen of the subject.  
 
Dr Henry Bence Jones, a renowned chemical pathologist at St. George’s Hospital in 
London, who analysed the urine sample, exerted this substance to be a hydrated 
deuteroxide of albumen with a high index of suspicion as part of a more extensive 
disease process. Mr John Dalrymple, a surgeon at the Royal Ophthalmic Hospital 
Moorfields, London examined Mr Mcbean’s diseased bone tissue and microscopically 
noted the presence of oval cells which were 1.5-2 times larger than red cells, with two 
nuclei each with a nucleolus. This was assumedly plasma cell(PC) description; 
however, the term itself was coined in Waldeyer in 1875 although the described cells 
were likely tissue mast cells. 
 
It was in the 1890s when an accurate description of PC with a typical microscopic 
appearance of an eccentrically positioned nucleus, a perinuclear pale area ‘hof' and 
irregular cytoplasm was characterised. Bence Jones proteins were increasingly iden-
tified as abnormal related to the disease process, independent of dietary intake of 
proteins in early 20th-century being of two different types (1922 Bayne Jones and 
Williams). It was Korngold and Lipari (1956) who identified the presence of urine free 
light chains with kappa and lambda light chains attributed to them for their work. 
Edelman and Gally demonstrated the identical amino acid composition of light chains 












MM is a PC proliferation disorder characterised by a monoclonal population of term-
inally differentiated mature B cells which presents with disease-related features 





The global incidence of MM is about 139 per 1000 cases with about 98 per 1000 deaths 
worldwide is also attributable to MM[4]. In the countries with high, middle and low socio-
demographic index it ranks 21st, 27th and 24th most common cancer in both sexes[5]. 
 
 
Fig3: Estimated age-standardized rates (World) of incident cases in both sexes 




It is the 14th most common malignancy and the second most common hematological 
malignancy that accounts for 1 to 2% of all cancers in the United States and has an 
annual incidence of approximately 4-5 per 100,000 in the developed world and the 
mortality of 4.1/100,000/year[7, 8]. It is more common in the population over 60 years 
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of age with about 10 % population under 50 and 2 % under 40 years at diagnosis. The 
median age at diagnosis is 69, and the median age at death is 75. The estimated new 
cases in the United States were 30,770 in 2018 with approximately 12,700 deaths 
secondary to the disease accounting for 2.1 percent of all cancer-related mortality. 
Encouragingly the death rates were falling by 0.5% each year between 2006-2015 with 
5-year relative survival percent at 53 in 2015 compared to 26.3 % in 1975[7]. The 
prevalence of MM IN US was estimated at 124,733 in 2015[7]. 
 
5,540 (two percent) of all newly diagnosed cancer cases in the United Kingdom were 
of MM in 2015 with almost 45% of new cases diagnosed in people over 75 years of 
age. Increased disease incidence rates are noted between 1992-1995 and 2013 to 
2015 by thirty-two percent with a more considerable increase in the male population. 
An estimated 11% increase in the UK between 2014 and 2035 is projected for MM 
incidence. Encouragingly overall survival has seen a fourfold increase in the UK in the 
last 40 years with thirty-three percent surviving 10 or more years[9]. 
 
Asian countries were initially noted to have a relatively lower incidence of MM. However, 
newer studies indicate a rise in incidence and disease-related mortality. Taiwan noted 
a fourfold increase in the incidence of MM [10]while Korea reported a tenfold increase 
in 2012[11] making it possibly the second most common hematological malignancy in 
the country[11].  The higher disease incidence and prevalence is likely indicative of 
improved health care and access to advanced diagnostics. 
 
In Latin America, while the incidence of MM appears similar to the overall incidence, 
decreasing incidence trends were reported in Ecuador (particularly for women) and 
Costa Rica[12]. Sub-Saharan Africa potentially under-reports its true incidence of MM 
in population given limited and skewed cancer registries available from these 
countries[13]. There is a higher incidence of MGUS in African Americans compared to 
the white population suggestive of possible similar results for the black population in 
Africa[14] 
 
The incidence of MM  is slightly higher in men when compared to women (1.4:1). MM 
is the most common hematological malignancy in the Black population along with 
earlier age of onset and 2-3 times higher incidence of the disease when compared to 
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the white population[14]. 
 
The prevalence of MM has also significantly increased. Reports from Sweden and 
Denmark show approximately a threefold increased disease prevalence between the 
1980s until post immunomodulatory era (Ref 6, 46). This could partly be due to 
increased patient survival and further autologous haematopoietic stem cell 
transplantations in eligible patients. 
 
 
Fig4: Estimated number of prevalent cases (5-year), both sexes, multiple 

















There is increasing evidence supporting a hereditary form of MM. Familial cases of 
MM are well documented[15-17]. Studies have demonstrated familial clustering of 
monoclonal gammopathy of undetermined significance (MGUS) particularly in first 
degree relatives with increased prevalence with increasing age to 12% for related 
probands between 60-69 years of age[17, 18]. Several case reports have highlighted 
upon the increased risk of disease transmission particularly in first degree relatives, in  
African American/Black families and male relatives within these family[19]. Genome-
wide association studies(GWAS) have identified several loci single nucleotide 
polymorphisms(SNP) which could potentiate the development of MM by enhancing 
transcription of proto-oncogenes such as MYC which are well known to be 
dysregulated in MM[20]. 
 
While initially speculated, no significant increased risk of MM was reported amongst 
survivors of the atomic bomb[21]. Increased risk of developing MM has also been 
associated with a high body mass index(BMI)[22]. The increased relative risk of 1.38 
of MM is noted in farmers, but no significant occupational exposures, infections, 
pesticides or solvents could show to be causal[23]. Exposure to hair dyes has also 
















1.4 B cell maturation and differentiation 
 
Once produced in the bone marrow, pro-B cells undergo first molecular differentiation 
with heavy chain immunoglobulin(Ig) gene(IGH) rearrangements. Stochastic DNA 
deletions first cause 1 of the 27 DH(diversity domain) segment to 1 of the 6 JH (Joining 
domain) segments. Pro-B cells which successfully undergo the first differentiation 
further differentiate by combining the formed DH-JH with the VH(variability domain) 
segment. Recombination activating genes(RAG) precisely regulate these 
rearrangements by pattern recognition of specific DNA segments within JH, DH and 
VH segments. 
 
Formed Pre- B cells next, undergo rearrangements in the genes for the light chains 
Kappa() and Lambda()(IGL and IGL) with IGL gene rearrangement occurs when 
a pre-B cell fails to undergo IGL gene rearrangement correctly. Hence these Mature 
B cells express IgM or IgM and exit the marrow after undergoing negative selection 
where surface IgM is mandatory to pass the checkpoint. Majority of mature B cells 
migrate to the spleen and lymph nodes where successive negative selections ensure 
the survival of specific mature B cells. These mature B cells are termed as Follicular B 
cells(FC B cells). A subset of mature B cells migrates to the marginal zone(MZ B cells) 
of the splenic sinus'. This convenient location facilitates an encount- er with various 
bloodborne pathogens and antigens possible. 
 
The smallest subset of remaining B cells termed as the B1 cells localises to the 
peritoneal and pleural mucosal regions monitoring these physiologically pathogen 
enriched sites. The MZ and B1 cells are inherently adept at responding to T cell 
independent antigens. They produce short-lived antibodies with fixed antigen affinity 
and form an essential early response to a foreign antigen; however, FC cells 
preferentially respond to antigens causing simultaneous CD4+ T helper cell activation. 
 
Antigen exposure via dendritic or T helper cells activates the FC cells and forms the 
germinal centres(GC) - the site of somatic hypermutation. These selective mutations 
permit selective survival of FC B cells which produce high-affinity Ig’s to the culprit 
antigen. This process leads another step in the development of antigen secreting 
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cells(ASC) called the B lymphoblasts which then undergo Ig class switch recombine- 
tion(CSR) expressing different Ig's; IgA, IgE and IgD becoming mature B cells in the 
process. These mature B cells are crucial for the formation of PC or memory B cell 
differentiating to produce ASC's on repeat antigen exposure. 
 
 
1.5 Pathogenesis  
 
1.5.1 Origin of clonal plasma cells(PC) 
 
Hamburger et al. first demonstrated the clonogenic MM patient PC’s by successfully 
growing colonies in vitro on soft agar plates with an efficiency ranging from 0.1 to 
0.001[25]. Since then, the origin of MM plasma cell(MMPC) disease has been much 
studied. Different studies have identified several possible origins of clonotypic MM cells. 
These clonal cells persist despite treatment and can be transplanted with use of growth 
colony stimulation factor(GCSF) mobilization into secondary hosts[26]. 
 
 
1.5.1.1 Clonal B cell origin 
 
Identical Ig gene sequences throughout the course of MM is indicative that the disease 
originated likely after B cell somatically mutated and formed ASC's. Identification of B 
cells harbouring Ig gene sequence and identical idiotype to the individual myeloma 
clone raised the possibility of a post-germinal B cell origin of MM [27, 28]. Further work 
by Matsui et al. by injecting CD19+ clonotypic B cell population from the peripheral 
blood sample of MM patients into Non-obese diabetic/severe combined 
immunodeficiency(NOD/SCID) mice and producing a mature CD138+ monoclonal 
plasma cell population in the mice indicated a B memory cell type precursor of the 
disease. Further, the engrafted CD19+ B cells from mice could be secondarily 
engrafted and produce the disease phenotype in the secondary recipient[29]. This 
monoclonal CD19+ Memory B cell type phenotype is resident to bone marrow(BM) 
niche and relatively resistant to most commonly used anti-myeloma therapy[27, 30, 31]  




The population of circulating clonotypic B cells increases with disease relapse in MM 
patients and can persist despite achieving a significant absence of PC frequency in the 
BM post bortezomib and autologous stem cell transplantation(ASCT)[32]. Further 
studies have indicated with changes in the cellular environment such as increased 
hypoxia can reduce CD138 expression/ or instead selectively promote CD20, CXCR4 
expressing stem cell-like phenotype. These cells with increased stem cell-like 
transcription factors sensitized to Bortezomib treatment post ATRA treatment[33]  
 
 
1.5.1.2 Clonal PC origin 
 
While work with clonotypic B cell in myeloma genesis shows promise, Chen et al. 
challenged the notion of clonal B cell origin of MM by showing that a minor proportion 
of circulating B cells in MM patients is clonally related to MMPC[34]. FISH-based 
assessment of bone marrow aspirates showed no significant association between the 
chromosomal aneuploidy in MM patients when comparing the B cell population and 
the monoclonal PC[35]. With the possibility of a B cell stem cell-like clonal origin of MM 
disease, It is hard to explain why CD20 depleted BM did not yield higher proportion 
and deeper response rates in MM patients treated with Rituximab[36] 
 
Yaccobi et al. successfully engrafted human MMPC’s in mice models enriched with 
foetal bones. The engrafted cells produced human Ig between 2-9 weeks of the 
transplantation and with hypercalcemia, osteoclast activation and selective foetal bone 
reabsorption[37]. Rawston et al. further identified CD138+/CD38+/VLA5- as markers 
of circulating and self-replenishing plasma cells using stringent flow based gating 
strategies[38]. 
 
Hosen et al. successfully demonstrated CD38 ++, CD138-/+ PC is capable of prod-
ucing MM in severe combined immunodeficiency(SCID) mice models, with a more 
rapid disease progression in CD138- cell population. Importantly these BM cells were 
deficient in B cells when secondarily transplanted to SCID-rab recipient to generate 
the disease[39].  These results are similar to those of Kim et al. who used more 
immunocompromised host mice with xenografted human foetal bone grafts to populate 
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patient's fully differentiated CD138+ CD38+ cells causing MM disease in the host mice 
which was transferable to secondary hosts[40]. 
 
Given the possible heterogeneity of cells indicates a heterogeneous PC population 
with several subclones. The clonal population sensitive to chemotherapy can be tidally 
taken over by the resistant subclone. However, several factors can be implicated in 
disease progression and resistance to chemotherapy including tumour promoting bone 
marrow microenvironment, activated signalling pathways,  genetic aberrations and MM 























1.6 Signalling pathways 
 
MM cells depend on direct and indirect interaction with surrounding milieu micro-
environment to maintain sustained growth, resistance to treatment and continued 
survival. These interactions cause dysregulated activation of signalling pathways 
within the MM cells which produce growth factors and cytokines for autocrine and 
paracrine influence on self and surrounding bone microenvironment. Mutations 
causing activation of some of these signalling pathways are prominently noted in active 
disease but not in MGUS or SMM stages. Currently used chemo-therapeutics target 
the signalling pathways implicated in MM. 
 
 
1.6.1 NF-kB pathway 
 
This family of five transcription factors ( RelA/p65), RebB, c-Rel, p50 and p52 widely 
regulate innate and adaptive immune responses. In a non-stimulated state, cells retain 
NF-kB in the cytoplasm bound to kB or Inhibitory(IkB). Stimulus triggering either the 
classical(canonical) or alternative(non-canonical) pathways causes either proteasomal 
degradation of IkB(canonical pathway) and nuclear translocation of NF-kB subunit or 
involves selective processing of p100(precursor of p50 and p52) and subsequent 
nuclear translocation of p52/RelB complex and gene activation respect-ively[41]. 
 
Activated NF-kB has been noted in 40% MM cell lines and between 17-20% primary 
patient tumours[42-44]. Transcriptional activation of genes including MAPK31, 
MAP3K14, RIPK4, TLR4, TRAF2, TRAF3, CYLD, cIAP1/2, NIK, LTBR, CD40, TACI, 
BRTC, CARD11, IKBIP, NFKB1, IKBRB and TNFRSF1A which affect dysregulation in 
classical and alternative pathways is reported in MM[44]. Selective activation of 
regulators involved in proliferation( such as LTBR, CD40, NIK) while switching off the 
inhibitory regulators(cIAP1/2, TRAF 2/3) abnormally activates NF-kB in MM[43, 44]. 
Current therapeutics notably IMIDS(immunomodulatory drugs including thalidomide 
and lenalidomide) and a proteasome inhibitor(PI) such as Bortezomib affect NF-kB 
signalling. IMIDS are suggested to inhibit proinflammatory cytokines such as IL-6 
which significantly upregulates pro-survival and proliferative signals in MM plasma 
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cells. IL-6 is one of the cytokines induced by activated classical NF-kB[45]. Bortezomib 
inhibits alternative NF-kB pathway however activates the classical pathway[46]. Hence, 
a significant anti-MM activity likely needs dual inhibition of classical and alternative NF-





MAPK(Mitogen-activated protein kinase) belongs to serine/threonine kinases with four 
central kinases- extracellular signal-regulated kinase(ERK), ERK5, p38MAPK (p38) 
and c-Jun N-terminal kinase(JNK)[48]. On activation by receptor tyrosine kinase 
(RTK)/G protein-coupled receptor inactive GDP bound RAS gets activated to GTP-Ras 
complex which phosphorylates its effectors including RAF/MEK/ERK and PI3K/Akt and 
TIAM1/RAC1 pathways[49]. These pathways are essential in regulating cellular 
differentiation, cytoskeletal dynamic changes and flux of cellular proteins. Dys-
regulation of these pathways is implicated in tumour survival and progression[49].  
 
Ras is arguably the most mutated oncogene with mutations in K-ras present in about 
50% in lung and 90% in pancreatic cancers respectively[49]. Three human RAS 
oncogenes include H-ras, N-ras and K-ras of which K-ras and N-ras are highly mutated 
in MM. Recent study using whole genome exome sequencing identified mutated K-
ras(21%), N-ras(19%) and BRAF(7%) in about 50%  MM patients[50]. RAS mutations 
were previously reported in 7% of MGUS patients with increasing frequency of 
occurrence to 45 % of patients with relapsed MM[51].  
 
Ras mutations are mutually exclusive and potentiate clonal heterogeneity[50, 52]. 
Higher frequency of such mutations at relapse likely suggests aggressive disease with 
likely increased drug resistance. N-ras mutations are associated with increased 
resistance to Bortezomib with reduced response rates(7% vs 53% in patients with 
mutant vs wild-type N-ras, p=0.00116) with shorter progression free survival(PFS) [53]. 
Raab et al. demonstrated treatment response to BRAF inhibitor vemurafenib in a 
BRAFV600E mutated relapsed refractory MM patient. The response was sustained until 
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de-novo NRAS mutation caused selective disease progression [54]. This highlights the 
importance of targeting therapy in MM patients.  
 
 
1.6.3 PI3/Akt/mTOR pathway  
 
Phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB or Akt)/mammalian target 
of rapamycin(mTOR) signalling is dysregulated in several malignancies and impacts 
cellular division, motility growth and survival[55]. Mutated oncogenic drivers such as 
PIK2CA and Akt1 are frequently altered in various cancers and are found in a high 
grade of malignancies[56, 57]. Activating mutation causing self-activation of the 
pathway has not been found in PI3 and Akt pathway as demonstrated by Ismail et al. 
who found one point mutation in PIK3CA gene in MM patients with equal presence of 
the same in healthy individuals underscoring the importance of the mutation[58]. It 
implies either cross-activation amongst various signalling pathways or surplus stimuli 
from the microenvironment such as IL-6, VEGF upregulates the pathway in MM.  
 
Insulin-like growth factor(IGF) causes phosphorylation of insulin receptor substrate 
(IRS) which activates Akt. Two important downstream isoforms of mammalian target 
of rapamycin(mTOR - evolutionarily conserved serine /threonine kinases) complexes, 
MTORC1 and MTORC2 are implicated in protein synthesis, inhibition of autophagy, 
glucose metabolism, cellular survival and proliferation. MTORC1 is essential for protein 
translation and cell growth while MTORC2 is involved in glucose metabolism, survival 
and proliferation. Negative feedback mechanisms are controlling the balance between 
the mTOR complexes and of the PI3K/Akt activation. These feedback mechanisms are 
noted to be altered in MM[55, 59].  
 
Fernandez et al. showed F box only protein(FBXO9) a constituent of ubiquitin-protein 
ligase complex which is overexpressed in hyperdiploid MM, causes proteasomal 
degradation of MTORC1 leading to MTORC2 driven Akt auto-activation during 
starvation. If MM microenvironment is reportedly hypoxic, this could have significant 




Peterson et al. identified MTOR interacting protein DEP domain containing TOR 
interacting protein(DEPTOR) mRNA anomalously increased in MMPC’s(28%) 4 folds 
compared to normal PC’s. This increase is mainly clustered in the non-hyperdiploid 
subgroup of MM patients harbouring translocations for Cyclin D1, CyclinD3, c-MAF or 
MAFB. DEPTOR was identified to inhibit negative feedback loop regulating PI3K 
activation by MTORC1 hence leading to activation of Akt[61].   
 
 
1.6.4 Signalling pathway crosstalk  
 
Signalling pathways in MM are not mutually exclusive and can also overlap in activating 
signalling making treatment challenging and likely contributing to treatment failure. 
Further, given receptor homology, signalling molecule could simultaneously activate 
multiple signalling pathways. IL-6 has been shown to activate the PI3/Akt kinase and 
Ras/MEK/ERK pathway[62]. ERK inhibition has been shown to upregul-ate PI3K 
activating the PI3/Akt kinase pathway in MM[63]. Vice versa, selective inhibition of 
activated Akt has been shown to upregulate phosphorylated Erk in MM cell lines. 
Synergism was seen with simultaneous inhibition of Akt using Pan-Akt inhibitor with 
MEK inhibitor in MM cell lines which were resistant to Akt inhibition and exhibited 
upregulated MEK/ERK pathway likely the cause of resistance[64]. Inhibition of another 
well-known pathway the Janus kinase(Jak)/ signal transducer and activator of 
transcription proteins(STAT)– Jak2/Stat3 which responds to IL-6 signalling inducing 
resistance to apoptosis in MM, has been shown to cause upregulation phosphorylated-
ERK and phosphorylated-Akt on inhibition using TG101209, a Jak2 inhibitor[65]. 
Several other mechanisms of cross-activation between the pathways have been 
reported. It would strongly underpin combination chemotherapy approach in the 








1.7 Chromosomal abnormalities  
 
Evaluation of cytogenetics in MM has significant implications for disease progression, 
presentation,  response to treatment and overall survival(OS). The use of FISH has 
superseded metaphase karyotype analysis. A more significant number of specific 
probes targeting the interface chromosomes yields increased detection of specific 
abnormalities which were cryptic to karyotypic chromosomal analysis; carried 
significant disease prognostication. 
 
 Broadly, molecular cytogenetic aberrations are classified as primary and secondary 
chromosomal abnormalities. This classification considers presence of primary chromo-
somal abnormalities in MGUS disease stage. Usually, primary chromosomal abnorm-
alities are either trisomies or translocations. Trisomies usually involve odd number 
chromosomes including 3, 5, 7, 9, 11, 13, 15 forming an aneuploid/ hyperdiploid 
karyotype. Primary chromosomal translocations involve locus for heavy chain immune-
globulin IGH On chromosome 14 along with associated chromosome partners which 
most frequently are located on chromosome 4, 6,11,16 and 20[66]. Other less frequent 
Primary chromosomal abnormalities involve IgH translocations involve unusual partner 
chromosomes and simultaneous trisomes with IgH transloca- tions[66].  
 
FISH abnormality Approximate 
frequency (%) 
Chromosome affected 
Trisomy(No IgH abnormality) 42 
 
Odd number chromosomes  







































Monosomy 14 without IgH 
translocations or trisomies 
4.5  
Other cytogenetic abnormalities in the 
absence of IgH translocations or 
trisomy(ies) or monosomy 14 
5.5  
Normal 3  
Table 1: Cytogenetic abnormalities in MM[67, 68] 
 
Primary chromosomal abnormalities have distinct characteristics. These events are 
observed at the MGUS  stage and are observed to be present in the majority of clonal 
PC population. These events are none-overlapping;  only one translocation involving 
chromosome 14 would be present in the driving clone of the disease; however 
secondary chromosomal abnormality could be simultaneously present.  
 
Secondary chromosomal abnormalities are deemed to be a feature of progressive 
disease and are usually reflective of an adverse prognostic outcome. These include 
Deletion 13q/ monosomy 13,  deletion 17p/ monosomy 17 And deletion 1p or  gain/ 
amplification of chromosome 1q. The secondary chromosomal abnormalities are 
understood to be a sub-clonal population defining event leading disease progression 
and eventual treatment failure.  
 
 
1.7.1 Chromosome numerical abnormalities (trisomies, hyperdi-
ploidy and hypodiploidy) 
 
Chromosomal aberrations are seen almost 90% of MM patients[69]. These are 
complex structural and numerical abnormalities similar to those seen in solid 
malignancies, however, are acquired in specific associations reflective of clonal 
evolution[70]. Smajda et al. assessed chromosomal aberrations in 208 MM patients 
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using conventional cytogenetics, identifying 166(66%) patients with distinct survival 
outcomes based upon numerical and structural chromosomal anomalies. Of these 75  
patients had hyperdiploidy(chromosomes 3,5,7,9,11,15,17 and 19) and 63 had hypo-
diploidy(pseudo hypodiploid, hypotetraploid - associated with chromosomal structural 
anomalies) noted in pre-treatment BMPC analysis. A median OS of 33.8 months for 
hyperdiploid patients compared with 12.5 months for hypodiploid patients (P<.001) 
was noted [71] 
 
Similar results are reported by Marun et al. where they observed a five year OS 
difference between hypodiploid and non-hypodiploid group of 10% vs 41% 
respectively(p=.0001)[72]. All studies noted an almost exclusive prevalence of 
recurrent IgH translocations including t(4;14)(p16.3;q32), t(11;14)(q13;q32) and 
t(14;16)(q32;q23) in the hypodiploid group suggesting a potential role in adverse 
survival outcome[69, 71-73]. 
 
 The impact of aneuploidy on translocations and High-risk cytogenetic features In MM 
patients was assessed by Kumar et al. in their study. Patients were divided based on 
the presence of trisomies into standard risk or high-risk features by FISH analysis. 
Median OS of high-risk vs standard risk patient was 3.9 years versus not reached 
(P<.001). Patients with High risk without trisomies vs high-risk with trisomies had 
median OS 3 years vs not reached(p<.001). Trisomies had a beneficial effect on 
patients with del17p or other high-risk translocations[67]. 
 
Hyperdiploid MM patients tend to be elderly with an increased predisposition for the 
bony disease. The mechanism of favourable impact on the patient prognosis of 
trisomies is not well understood however could be related to increased translation of 
proteins regulating cell growth and apoptosis[74]. Another possibility could be the 












This is the most common IGH translocation in MM patients and is considered one of 
the primary cytogenetic events given its increased frequency in MGUS. By FISH it is 
identified in 10 to 20% of MM patient by FISH and portends a standard risk MM with 
median overall survival of 7 to 10 years[75-79].  t(11;14) has a higher prevalence in 
MM patients under 40 years of age. There is a higher proportion of IgD, IgE, IgM, non-
secretory, light chain disease and increased bony involvement noted in this 
subgroup[80, 81]. Patients with plasma cell leukaemia(PCL) have a higher frequency 
of t(11;14)[82]. The involved breakpoints during the translocation place the proto-
oncogene cyclin D1(CCND1) under IGH enhancer regulatory control. This 
hypothetically should accelerate the cell transition between G1 and S-phase. However,  
low plasma cell proliferation indexed were noted by Fonseca et al. In their study within 
this patient cohort[75, 78]. 
 
t(11;14) is conventionally a standard risk cytogenetic abnormality. However, treatment 
responses in this subgroup have been inferior in comparison to other standard risk 
abnormalities but superior to high-risk translocations. 
 
An G et al. demonstrated diverse treatment responses to bortezomib based treatme-
nts based on CD20 expression profile in this subgroup. OS outcomes of patients 
expressing CD20 in comparison to non-CD 20 expressers was superior(54 months vs 
16.5 months p=0.016)[83]. Another study compared outcomes of MM patients with 
either t(11;14), Normal cytogenetics/FISH or high-risk features undergoing ASCT. This 
study reported a 3-year OS of 83 %, 63% and 34%(p=<0.00001) respectively between 
the three groups[84]. 
 
Lakshman et al. In their study showed short and inferior OS of t(11;14) patients 
compared to standard risk MM patients with no impact of induction therapy on OS in 
this patient cohort. The median OS for non-translocation vs non-t(11;14) vs t(11;14) 
was 103.6( 95% CI, 85.2-112.3) vs 49.8(95% CI, 40– 60.6) vs 74.4(95% CI, 64.8–89.3) 
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t(4:14) is the second most common IGH translocation seen in 10 to 15% of MM patients 
and about 25% of MM cell lines representing breakpoints on chromosome 4 within the 
proximity of FGFR3 and MMSET exon 5[86, 87]. It is also noted to be less frequent in 
MGUS versus SMM and MM with a higher incidence in the patient under 66 years of 
age[88].  
 
One of the important translocation events is the up-regulation of FGFR3 gene 
transcription due to IgH promoter. It dysregulates the gene transcription with resultant 
increased FGFR3 signalling pathway. FGFR3 signalling activates RAS-RAF-MAPK, 
PI3K-AKT-mTOR, PLC, protein kinase C(PKC) and STAT pathways. 25-30% MM 
patients with t(4:14) do not express FGFR3 likely due to loss of FGFR3 gene during 
translocation to 14q chromosome arm however MMSET is expressed in the majority 
of this group of patients[87, 89]. 
 
MMSET is widely expressed in other malignancies as well and has been associated 
with tumour aggressiveness[90, 91]. MMSET(NSD2  or WHSC1  1 in mammals) has a 
role in double stranded DNA damage response as it mediates methylation of Histone 
H4 lysine 20(H4K20) at DNA double-stranded break site and regulates the recruitment 
of p53 binding protein 1(53BP1) following DNA damage via H2AX-MDC11-MMSET 
pathway[92]. All cases of Wolf Hirschhorn syndrome invariably Also loose the mapped 
region MMSET with the loss of Wolf-Hirschhorn syndrome critical region at 4p16.3. 
 
t(4;14) is undetectable using conventional cytogenetics( g banding) all spectral 
karyotyping due to the telomeric location of translocation and is detected by reverse 
transcriptase polymerase chain reaction(RT-PCR)  or iFISH[78].  Interestingly, 30% of 
patients with t(4:14) lack FGFR3 expression. However, this patient population 
maintains a poor prognosis highlighting that  likely dysregulation of both the genes is 




Study % t(4;14), 
(N= total 
patients) 
















































14 (184) 5.5 10.6 9.4 15.4 Len/Dex 
Chan H et 
al.[99] 
75 (75) 33.5  69.6  HDT/ Chemo 
alone 
Table 2: Important studies evaluating outcomes of patients with t(4; 14). Adapted 





t(14;16)   presents in about  2- 10% of MM patients. It is cryptic to detection wire 
classical karyotyping and was first identified using southern blot assay with an 
associated c-MAF translocation. MM cell lines including MM.1, JJN3, KMS 11 and 
ANBL6  express c-maf secondary to t(14;16). 
 
Several studies have shown shorter PFS and OS in MM patients with t(14;16). 
Fonseca et al. Identified 15 t(14;16)  patient in their analysis of 351 patients treated 
with conventional chemotherapy on Eastern co-operative oncology group clinical trial 
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E9486/9487. Median OS of t(14;16) vs without abnormality was 16( 95% CI 13 - 22)  
vs  41( 95% CI 37-48) months respectively (p =.003)[101]. Conflicting results were 
noted by Avet Loiseau et al. in the retrospective analysis where they did not find the 
statistically significant overall survival difference between similar patient groups [102]. 
The Gene Expression Profiling(GEP) in the TT3 Study on maintenance VRD high-
lighted distinct inferior outcomes in MAF/MAFB expressing patient subgroup[103].  
 
Another recent study evaluated treatment responses in 123 t(14;16) MM  patients 
receiving PI, IMID drug or a combination of both as induction followed by either 
consultation with an ASCT or maintenance treatment. The PFS and OS for the entire 
cohort were 19 and 53 months respectively. PFS and OS in transplant-eligible patients, 
those who received ASCT compared to those who did not, was 31 vs 10 
months(p=.003)  and  58 vs 34 months( p=0.04)  respectively.16 months PFS and 59 
months OS in ASCT ineligible patients. Maintenance treatment was noted to have 
favourable impact on PFS(36 vs 19 months,  HR 0.56; p =.03)[104]. 
 
Clinically,  increased incidence of PCL at presentation and light chain disease with 
subsequent renal involvement have been reported in these patient[102]. Median OS  






Limited data is available due to a low frequency of t(6;14) Present in approximately 2-
4% of MM patients. Functionally this translocation overexpressed cyclin D3 which 
phosphorylates RB to regulate G1/S cell cycle stage[78, 105]. It is classified as a 
standard risk genetic abnormality in multiple myeloma. It is present in other b-cell 
malignancies including non-Hodgkin's b-cell lymphoma, splenic marginal zone 
lymphoma and is implicated in oncogenesis of these mature b-cell malignancies[106, 








Its prevalence is noted to be 1.5% in MM and SMM patients However is unexpectedly 
high in MGUS(5%)(p= 0.005)[88]. There is a predominance of IgG isotype, advanced 
stage disease reported in this patient population. The juxtaposition of the MAFB gene 
to IGH enhancer causes increased in the gene transcription with a resultant increase 
in MAFB which is an AP1 superfamily transcription factor[108]. Up-regulated gene 
expression of MAFB has been noted in MM cell lines carrying t(14; 20) And is the likely 
oncogenic driver of poor prognosis in patients. Interestingly a majority of these cell 
lines came from patients with PCL younger than 65 years of age with the predominance 
of IgG isotope[109]. MGUS/SMM patients with t(14;20) appear relatively stable in the 





Monosomies in MM predict a poor OS outcome. Smadja et al. in their study showed 
an OS difference between hyperdiploid and hyperdiploid patients of 33.8 vs 12.6 
months(p < .001)[71]. 
 
 Chromosome 13  deletions are a frequent cytogenetic abnormality with majorly  
monosomy 13( 85%) noted and less frequent del13p(7-15%)[110, 111]. Initial studies 
indicated poor OS survival for patients with monosomy 13[112, 113]. However other 
studies identify it as a pre-requisite to clonal expansion and likely less significant due 
to the confounding effects of simultaneous adverse cytogenetic aberrations. A more 
recent study identified a protective role of partial deletion of chromosome 13 in contrast 
to the adverse prognostic effect of monosomy 13[111]. This difference was likely under-
highlighted due to smaller sample size of previous studies [114]. Monosomy of 
chromosome 2, 3, 13, 14 and 19 was associated with a  significantly poor OS[72]. Shin 
et al. Further identified monosomy 16 and loss of y chromosome as adverse prognostic 





1.7.4 Chromosome 1 amplification/deletion 
 
Chromosome 1 aberration present in about 40 to 50% of multiple myeloma patients. 
These include  1q  gain or 1p loss. Specifically, 1q21  amplification is unusual in MGUS 
and increases in the frequency of up to 45% in SMM 43% in newly diagnosed mm and 
72% in patients who have relapsed. It is generally considered a secondary event after 
dysregulated FGFR3/MMSET or c-MAF.  About 91% of myeloma cell lines of human 
origin have been shown to express 1q21 amplification[116]. Several mechanisms are 
implicated in 1q  primarily due to peri-centromeric instability causing the whole arm or 
jumping translocations. Shaughnessy et al. analyzed  532 newly diagnosed mm 
patients to identify a high-risk genetic signature subgroup with shorter duration of 
response. 30% of aberrant Gene expression mapped to chromosome  1q( upregulated 
genes)  and 1p(downregulated genes)[117]. Other studies have also shown inferior OS 
in patients with aberrant chromosome 1 abnormalities including 
deletions/amplification[72, 118, 119]. CKS1B, a common upregulated gene has been 
shown to portend aggressive disease course with shorter progression-free survival 
post-ASCT[120]. Other candidate target genes upregulated include MCL-1, BCL-9, 
IL6R, PSMD3, PSMB4, UBE2Q and others[121]. Leone et al. examined CDKN2C 
deletions associated with the 1p arm in 515 MGUS, SMM and newly diagnosed MM 
with either hemizygous or homozygous deletions at 1p32.3(CDKN2A). Loss of 
CDKN2A  was associated with poorer OS as compared to controls( 22 vs 38 months; 
p=0.003)  respectively[122]. Hebraud et al. found 1p32(7.3%) and 1p22(15.1%) to be 
independently negative prognostic markers for PFS and OS when compared to the 
patient population without the 1q aberration[123]. Another associated gene 
deleted/mutated at locus 1p12 is FAM46C which interestingly is associated with 
adverse prognosis in MM patients post-ASCT[124]. 
 
 
1.7.5 Del17p/Monosomy 17 
 
Loss of functional tumor suppressor gene p53(p53), is an unfavorable high-risk genetic 
aberration in MM identified as deletion(del17p13.1/del17p) on FISH or monosomy 17 
on karyotype[125]. These are considered subsequent events given increasing 
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incidence with disease progression or relapse[126]. Mutations in the chromosomal 
region are rare(3%); however increase with disease progression[127, 128]. Almost 
certainly, these mutations are associated with del17p portending an adverse OS [128-
130]. Del17p13.1 is frequent and have been reported in about 11% of patients with 
newly diagnosed MM[69, 78, 131]. MM patients with del17p have a poor prognostic 
outcome despite the use of newer therapeutic combinations[132].  
  
P53(17p13.1) regulates major pathways of cellular homeostasis in stressed or 
damaged cells[133]. Its functional loss exists in more than 50 % of human cancers 
[133-136]. Functional loss of p53 in MM is associated with a poor disease outcome 
and frequent uncommon MM presentations including EMD and PCL [137-139]. 
Although some treatment response has been reported with Bortezomib based 
regimens[24, 25], patients with Del17p usually achieve unsatisfactory survival benefits 
to novel agent treatment and/or  ASCT, when compared to the MM patients without 



















MM cell bone marrow localization is analogous to ‘seed and soil’ explanation of tumor 
specificity for different milieu favorable for the growth of the tumor cells[143]. No 
significant cytogenetic/FISH abnormality delineates progression from MGUS to active 
myeloma which suggests the role of extrinsic factors including the microenvironment 
in facilitating disease progression. However, >=95% aberrant plasma cells and 
chromosomal aneuploidy are risk factors associated with disease shift from benign to 
active disease[144, 145].  Several studies have identified the importance of cellular 
and acellular components of the bone marrow which are facilitative to the growth and 




1.8.1 Myeloma derived suppressor cells(MDSC) 
 
MDSC are immature myeloid cells which interact with PC’s promoting their proliferation 
and overcoming immune effects of therapeutic agents. These cells were identified over 
a decade ago, however, have been shown to have significant roles in cancer systems 
promoting treatment resistance, immune escape and anergy. Though first studied in 
mouse models where two phenotypes, granulocytic MDSC(G-MDSC) and monocytic 
MDSC(Mo-MDSC) bearing CD11b+ Ly6Ghi Ly6Clow and CD11b+ Ly6G- Ly6Chigh 
respectively were identified. G-MDSCs have increased levels of reactive oxygen 
species while the Mo-MDSCs have higher nitric oxide[146, 147]. In humans, G-MDSC 
are CD11b+ CD33+ HLA-DR-/low CD14 – and Mo-MDSC are CD11b+ CD33+ HLA-
DR-/low CD14+. MDSC’s increase in peripheral blood and bone marrow of MM 
patients with increasing frequency corresponding with disease 
progression/relapse[148]. These cells show a prominent increase in the BM of MM 
patients suggesting a potential significance in the MM disease potentiation[149]. 
Further, Mo-MDSC’s activate STAT1- dependent gene promoting nitric oxide-mediated 
T-cell suppression while G-MDSC likely mediates the same via increased levels of 
reactive oxygen species which are undetectable in Mo-MDSC’s and vice-versa[147, 
149, 150]. There is bi-directional crosstalk between MM cells which have been shown 
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to induce MDSC’s which also facilitates MM cell growth in the microenvironment. 
Further, Gorgun GT et al. highlighted that the number of MDSC’s and their immune 




1.8.2 T cells and natural killer(NK) cells 
 
T cells dysregulation is a notable feature of bone marrow microenvironment in MM 
patients. There is increasing evidence supporting the accumulation of subsets of T 
helper cells including Th1, Th2 and Treg in MM patients when compared to the normal 
population. While the Th1/Th2 subset disbalance in favour of Th2 subset further 
facilitates an increase in Treg subset which are known to be involved in self-
tolerance[151-153]. One of the noted mechanisms is via self-tolerance induced by 
plasma cells that behave as immature antigen presenting cells expanding the Treg 
cells likely inhibits anti-MM immune response[154]. MM bone marrow has increased 
IL6, TGF, and IL1 cytokine levels secreted in the microenvironment[155, 156]. These 
cytokines have been shown to facilitate Th17 development which secretes IL1, IL13, 
IL17 and IL23. MM cells express IL17 receptor and proliferate in the presence of the 
cytokine as shown in SCID mouse models and in-vitro experiments[157]. Importantly 
IL17 levels positively correlate with progressive/advancing MM disease and are 
implicated in enhancing secretion of angiogenic factors including VEGF, TNF and 
microvessel density, by BM cells[158]. 
 
Natural killer cells are a separate lymphocytic lineage with cytotoxicity and cytokine-
mediated effector response. Inherently they can recognize self from foreign cells via 
expression of MHC class one specific receptor. This recognition allows NK cells to 
selectively target MHC class one deficient haematopoietic stem cells while ensuring 
tolerance to self-cells. Other stress-induced ligands recognized by the NK cells include 
NKG2D, TLR and several infectious nonself ligands. In vitro, the interaction of NK cells 





A notable escape mechanism of multiple myeloma plasma cells from NK cell-mediated 
lysis is by shedding of MHC class I chain-related protein A (sMICA) l ligand, a 
recognized target of NKGD2 receptors expressed on NK cell-surface[160]. Another 
implied mechanism of resistance is the reduced number of NKG2D expressing effector 
cells in MM patients[161]. 
 
 
1.8.3 Dendritic Cells 
 
Dendritic cells are known as the master regulator of the immune system. They are 
responsible for optimizing the immune response by activating the T cells via major 
histocompatibility complex (MHC II) class II-mediated antigen presentation. Efficient 
functioning of dendritic cells a high-level expression of MHC II antigen and co-
stimulatory molecules (including CD86, CD83, CD80 and CD40) which are implicated 
in activating naïve and memory T cells[162, 163]. 
 
Several mechanisms of dendritic cell dysfunction are identified in MM patients. While 
phenotypic and functional abnormalities of DC from MM patients potentially causes 
defective immune response; Micro-environment of MM patients is known to have a 
higher degree of  IL6, VEGF and M-CSF which compromises DC’s process of T-cell 
antigen presentation[164-166]. Increased IL6 levels are associated with activation of 
P38 MAPK pathway which inhibits DC maturation and impacts migratory functions in 
MM patients. Further, it has been highlighted that not only a reduced number of DC in 
MM patients but also a reduced ability to secrete the T cell stimulatory IL12p70 which 
promotes T-helper cell 1(Th-1) differentiation. This affects the Th1 cytokine interferon-






Macrophages are an essential component of mononuclear macrophage lineage and 
are hence related to the dendritic cell. They are conventionally known to differentiate 
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into activated macrophage 1(M1) or activated macrophage 2(M2) in response to 
various environmental stimuli and growth factors. M1 type has higher expression of 
MHC II, IL12 and tumour necrosis factor alpha(TNF) playing a specific role in nitric 
oxide and reactive oxygen species-mediated anti-pathogenic activity. The M2 type of 
differentiation in response to IL4 and IL13 is usually a facilitator of Humoral immunity 
and wound healing[167]. It is shown that monocytes are selectively biased towards a 
more distinct population of M2 type which facilitates tumour growth and resistance to 
chemotherapy. 
 
Zheng et al. identified that CD68+ macrophages heavily infiltrated the bone marrow of 
MM patients and further conferred protection against chemotherapy-induced apoptosis 
by down-regulating cleavage of caspase-dependent apoptosis[168]. These tumour 
associated macrophages(TAM) express P/E selectin and CD18 which can interact with 
P– selectin glycoprotein ligand 1(PSGL-1) and intracellular adhesion molecule 
1(ICAM-1) on MM cells respectively to induce multidrug resistance in MM patients by 
activating SRC, ERK 1/2 and c–MYC which inhibited drug-induced caspase 
activation[168, 169].  
 
Macrophages are a source of cytokines including VEGF, FGFR2, IL1, IL6 and IL8 
stimulating the surrounding BMSC’s and enhancing MM associated 
neovascularization[170-173]. Stimulated BMSC’s in MM patients are a source of IL6 
which drives MM cell proliferation. Further, via toll-like receptors (TLR) 2/6 activation, 
a more inflammatory phenotype of macrophages is persistently producing IL6 and IL1 
promoting MM cell proliferation and BMSC’s IL-6 production[174]. 
 
 
1.8.5 Bone marrow stromal cells (BMSC’s) 
 
Bone marrow stromal cells are important modulators MM microenvironment. They are 
known to express a higher level of intracellular adhesion molecule 1(ICAM-1), vascular 
cell adhesion molecule 1(VCAM-1) promoting PC adhesion and activation of signalling 
pathways such as NF-KB, Notch[175, 176]. These pathways induce growth factors 
such as IL6, VEGF, IGF1 which promote MM cell survival and proliferation. Nefedova 
47 
 
et al. demonstrated increased sensitivity of MM cells to conventional chemotherapy by 
inhibiting Notch signalling[177]. Similarly, NF-KB inhibition is one of the targets of 
Bortezomib in MM[178].  
 
Bone marrow stromal cells further communicate with  PC via secreted exosomes which 
are between 40 to 100nm sized membranous vesicles containing miRNA that can 
regulate their proliferation.  Recaro et al. first identified downregulated mir15a  in 
exosomes derived from primary MM BMSC when compared to primary normal 
BMSC[179]. Wang et al. further demonstrated BMSC derived exosomes increase PC 
migration, proliferation, survival and resistance to bortezomib by reduced, increased 
expression of Bcl-2 and cleavage caspase 3, caspase 9 and PARP [180]. MM-derived 
BMSC’s have been shown to support increased growth of CD184 expressing 
population of RPMI cell line compared to BMSC derived from non-MM patients 
highlighting an essential role of supporting stem cell-like MM cells[181].   
 
 
1.8.6 Osteoblasts and Osteoclasts:  
 
MM microenvironment is permissive to osteoclastogenesis while selectively inhibiting 




1.8.6.1 Molecular pathways facilitating osteoclastogenesis 
 
a) RANK/RANKL: Receptor activator of nuclear factor(NF)-B(RANK) and RANK 
ligand(RANKL) bone remodelling associated signalling pathway is dysregulated in 
MM. RANK receptor and RANKL interactions facilitate osteoclast precursors to 
fuse and form a mature osteoclast(OC). This interaction is inhibited by the decoy 
receptor osteoprotegerin(OP), which is secreted by marrow stromal cells(SC) and 
OB. The balance of RANK/OP is raised in MM patients, favouring increased OC 





b) Notch signalling pathway: This pathway is well described in osteoclastogenesis. 
Via homotypic and heterotypic interactions between adjacent MM cells and MM 




1.8.6.2 Molecular pathways associated with osteoblast inhibition 
 
c) WNT pathway: Wingless and integration-1(WNT) pathway is well described to 
enhance gene expression facilitating bone formation. When the canonical arm of 
the pathway is activated facilitating translocation of cytoplasmic -catenin to the 
nucleus; it induces T cell factor/lymphoid enhancer factor (TCF/LFE) transcription 
factors resulting in gene expression of proteins implicated in bone anabolism[184]. 
 
These pathways are complemented by the simultaneous activity of various 
cytokines/secreted ligands/receptors and transcription factors which in MM are 
pro- osteoclastogenesis and catabolic. Most important ones are mentioned  below: 
 
a) Interleukin 3: Cytokine implicated in osteoclastogenesis by inducing BM 
macrophages to produce Activin A (transforming growth family  - TGF family) 
protein which causes RANK expression. RANK further via the NF-B pathway 
leads to osteoclast maturation[185] 
 
b) Interleukin 6: Improtant cytokine secreted by myeloid cells, known to stimulate 
MM cells into secreting VEGF and more IL6 which improves MM cell survival. 
VEGF further activates osteoclastic surface receptors stimulating differentiat-
ion[186, 187] 
 
c) Interleukin 7: Plays a dual role of 1) Downregulating Runt–related transcript-ion 
factor 2/ core-binding factor Runt domain subunit 1(RUNX2/CBFA1)  which 
affects non-canonical WNT pathway known to impede osteoblast-ogenesis[184, 




d) Interleukin 17: Secreted by T helper cells which are likely induced by dendritic 
cells(predominant antigen presenting cell in BM niche of MM patients). IL17 is 
a known osteoclastogenic pro-inflammatory cytokine implicated in bone 
disease[190-192] 
 
e) MIP- 1/CCL-3: Pro-inflammatory cytokine expressed by stromal cells and 
hematopoietic stem cells further produced by MM cells. Potent osteoclast 
activator stimulating osteoclast differentiation. In MM, enhances plasma cell 
and stromal cell interaction inducing RANKL and IL6 propagating tumour 
burden with bone destruction[193-195]. It further activates PI3-K/Akt and MAPK 
pathways in MM cells, potentiating plasma cell growth, resistance to cell death 
and migration[196, 197]. Further evidence suggests CCL3 dysregulates the 
osteoblast/osteoclast balance by inhibition of osteoblastic differentiation, 
favouring overall bone catabolism in MM[198, 199] 
 
f) TNF: Tumor necrosis factor-alpha is a member of TNF superfamily involved 
in osteoclastogenesis. TNF vial RANKL stimulates osteoclast differentiation 
[200] which is suggestively mediated via TNF type 1 receptor(TNFr1)[201] 
 
g) BTK: Burton’s tyrosine kinase, a non-receptor tyrosine kinase[202] implicated 
in osteoclast differentiation and migration towards MM plasma cell via crosstalk 
with CXC chemokine receptor type 4(CXCR4 – levels positively correlate to 
BTK expression in MM cells) and SDF-1 (stromal cell produced cytokine)[203-
205]. SDF-1 activated BTK in MM cells while facilitating osteoclast precursors 
with coexpression of CXCR4 and BTK to migrate towards MM plasma cells[204, 
206]. 
 
h) Dkk: Dickkopf-1, a WNT inhibitor protein secreted by MM plasma cells which 
interferes with canonical WNT pathway, preventing  catenin nuclear 
translocation and ultimately preventing osteoblast differentiation[207]. Increa-
sing levels of Dkk corresponds to increased lytic lesions and advanced MM 
compared to significantly lower levels in MGUS and WM(Waldenstrom 
macroglobulinemia)[208]. Decreased osteoblasts could favour RANK/OP ratio 
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to drift augmenting osteoclastogenesis and additively worsening lytic bone 
disease[209, 210] 
 
i) Activin A: TGF superfamily member which via canonical (ActRIIA/B receptor-
mediated phosphorylation of activin receptor-like kinase 4-ALK4 induces Smad 
signalling with translocation of transcription factor Smad2/3/4 complex into the 
nucleus) and non-canonical(Akt/PI3K, MAPK/ERK, JNK and WNT/-catenin) 
pathways induces osteoclastogenesis and inhibits osteoblast devel-
opment[185, 211] 
 
j) Sclerostin: Anti-osteoblast protein (antagonistic to bone morphogenic protein -
BMP’s; adversely affecting BMP mediated osteoblastic mineralization), secre-
ted by osteocytes by binding the LRP5/6 transmembrane receptors and 
preventing WNT mediated DVL-Axin-FRAT1-GSK3 complex formation. This 
causes phosphorylation of  catenin and proteasomal degradation via 
ubiquination[212-214] 
 
k) Osteopontin : (OP) Is a glycoprotein secreted by different cells. In MM it has 
been noted to be secreted by MM cells and expressed in elevated levels by 
patient stromal cells. OP is increasingly expressed with evolving MM from 
benign MGUS to active disease with correlation to osteolytic disease 
burden[215-217] 
 
The above mentioned signalling pathways/molecules along with inter and intracellular 
interaction have provided the basis of several pre-clinical/clinical drug testing. One of 
the most recent successful examples would include Denosumab. Recent data shows 









1.8.7 Vascular component and non-cellular compartment 
 
Incremental BM micro-vessel density(MVD) has been shown with progressive disease 
spectrum with minimal MVD in MGUS to a progressive increase in active MM [219]. 
There are increased transcription factors such as hypoxia-inducible factor 
1alpla(HIF1) which can regulate VEGFA, IL-8 and other pro-angiogenic molecules in 
MM patients[220]. CD138+ cells from MM patients reportedly have increased 
transcription of different signalling molecules including heme oxygenase 1(HOMOX1), 
Heat-shock protein(HSP) and XIAP(X - linked inhibitor of apoptosis)[220]. 
Experimentally, HSP70 inhibition reverses melphalan-induced cell adhesion mediated 
and acquired drug resistance. HSP70 inhibitors further induced increased apoptosis in 
melphalan induced drug resistance[221].  Levels of hepatocyte growth factor(HGF), 
TNF and MVD are correlative of MM disease burden with decreased levels on 
treatment response[222].  
 
Other notably deranged growth factors include VEGF, basic fibroblast growth factor 
(bFGF), angiopoietin-1(Ang-1), matrix metalloproteinases(MMPs), osteopontin(OPN), 
IL-6 and IL8[223]. Hose et al. proposed that bone marrow angiogenesis is normally 
under the regulation of BMPC’s and can be disrupted by MM cells by stimulating 
angiogenesis and downregulating anti-angiogenic genes[224]. Another mechanism of 
vasculogenesis involves monocytic differentiation into endothelial cells when exposed 
to pleiotrophin(PTN) an angiogenic factor produced by MM plasma cells re-
emphasizing the role of MM in facilitating a pro-angiogenic BM micro-environment[225]. 
 
 The non-cellular component or extracellular matrix(ECM) forms a supporting 
meshwork of about 300 proteins including cellular component(fibroblasts), collagens, 
proteoglycans and glycoproteins, enzymes(matrix metalloproteases -MMP) and 
signalling molecules(cytokines and growth factors) which regulate cell survival, 
proliferation and metastasis along with MM cell crosstalk[226, 227]. ECM related 
receptors and modulating enzymes including Laminin-, lysyl-hydroxylase 2, prolyl 4-
hydroxylase 1, nidogen-2, MMP2 and others were shown to be upregulated in MGUS 
and MM compared to control patient’s human fibroblast-like cells[228]. Another study 
reported the detection of Annexin A2(ANXA2) and Galectin-1(LGALS1) expression in 
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MM patients; however, not in healthy patients or MGUS patients and correlates with a 
decreased OS[229, 230]. Both these proteins are ECM proteins implicated in cell-cell 
and cell-matrix interaction and have a role in promoting MM growth and induced 
angiogenesis[229, 231]. Interestingly, Galectin-1 expression is downregulated by 
knockdown of HIF-1alpha[231].  
 
Integrin fibronectin receptors(VLA-4, VLA-5) adherence to MM cells causes cell 
adhesion mediated drug resistance(CAM-DR) to doxorubicin and melphalan 
suggestive of direct MM cell and ECM interaction mediated conventional 
chemotherapy resistance[232]. Interestingly, Bortezomib can inhibit CD49d(4-integrin) 
a subunit of VLA-4 and can overcome CAM-DR resistance sensitizing them to other 























Kyle et al described 73% patients present with Hb<12g/dL at diagnosis of MM which is 
usually normocytic and normochromic[234] with sub-optimal reticulocyte response 
(reticulocyte index <2.5%)[235]. The degree of anaemia can also be reflective of 
disease activity with low borderline values usually in MGUS. Kyle et al. showed the 
presence of anaemia in 23% of one thousand three hundred and four MGUS patients 
which was attributable to non-PC activity related causes(myelodysplasia, renal insuf-
ficiency and iron deficiency)[236]. The number of patients presenting with Hb< 12g/dL 
increases to 76% in patients with SMM[237]. Further, 97% of patients with MM would 
experience some degree of Anemia[234]. Manifestations of anaemia include fatigue 
and poor quality of life that would worsen the prognosis for patients with concurrent 
cardiovascular co-morbidities. 
 
PCs infiltrating the bone marrow can disrupt the erythroblastic islands(EBI) by direct 
unit displacement and further by secretion of cytokines and mediators which affect 
growth and development of maturing erythrocytes. Secretion of Fas ligand (FL), tumour 
necrosis factor related apoptosis-inducing ligand (TRAIL), further impedes normal 
erythropoiesis[238]. Further likely cleavage of GATA-1(transcription factor promoting 
erythroblastic differentiation and survival) by FL and TRAIL, would globally stunt 
erythroid development in MM[238, 239]. This would theoretically imply improved 
erythroid development post-MM treatment. Bouchnita et al. demonstrated an incr-ease 
in Hb levels, erythrocyte count and marrow erythroid precursors in patients with pre-
treatment 30% MM infiltration of BM who received lenalidomide/bortezomib-based 
treatment[240]. It would indicate that anaemia in MM is reversible with appropriate 
disease control. Common causes implicated in MM related anaemia would include: 
 
1) Infiltration of bone marrow by the malignant plasma cells 
2) Negative effect on growth and development of erythrocytic precursors by MM cells 
via FAS ligand and TRAIL-mediated cytotoxity[238, 241] 
3) Renal impairment/erythropoietin deficiency 
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4) Anaemia secondary to the folate/B12 deficiencies 
5) Falsely low due to hemodilution secondary to the M protein 
6) Chronic inflammation related to a low normal iron, high ferritin and increased 
hemosiderin in the bone marrow 
7) Anaemia secondary to chemotherapy – hypoplastic 
8) Anaemia secondary to bleeding related to amyloid deposits/coagulation defects – 
secondary IDA 
9) Hemolysis/traumatic causes 
 
Managing symptomatic anaemia involves either red cell transfusion or use of 
supportive treatment with erythropoietin stimulating agents(ESA). While transfusion 
requirements improve with therapy related disease control, Erythropoietin (EPO) levels 
are typically reduced in renally impaired MM[242] and would necessitate repletion for 
improved Hb level. Treatment with ESA is controversial in MM. Cancer-related 
anaemia improves subsequent to its usage along with positive correlation of 
subjectively improved quality of life, proportional to the degree of normalization of Hb 
levels [243]; there is an increased risk of hypertension, thrombosis and potential 
antibody mediated erythroid aplasia[244]. 
 
Current recommendations with use of ESA suggest a trial when Hb concentration is 
<10g/l, particularly in patients with anemia secondary to renal failure, having ruled out  
alternative causes of anaemia[245]. 
 
 
1.9.2 Bone disease and hypercalcemia 
 
Bone structural abnormalities, pain and fractures are hallmark features in MM and are 
well-documented features, historically notable with the case of Sarah Newbury, the first 
described case of MM[3]. About 60% of patients with MM present with bone pain at 
diagnosis with over half of those experiencing moderate to severe pain[234]. Another 
study highlights that risk of fractures increases by nine fold along with 69% patients 
developing pathological fractures post MM diagnosis predominantly in the vertebrae 




MM is also shown to have the highest prevalence of hypercalcemia(serum corrected 
calcium >11g/dL)  when compared to other osteolytic malignancies [247]. About 20% 
of newly diagnosis MM patients have hypercalcemia at presentation, although it is 
rarely the only presentation of symptomatic disease[247, 248]. Survival outcome of a 
patient with hypercalcemia worsen with increasing degree of hypercalcemia[247] as 
outlined by the Durie Salmon Staging (DSS). Further, hypercalcemia is a marker of 
adverse disease despite the use of newer agents[249] warranting a deeper 
understanding of the mechanism for effective management strategies. 
 
Bone metabolism and subsequent remodelling is complex and is dysregulated by 
several mechanisms in MM predominantly augmenting the osteoclast(OC) activity 
while suppressing the osteoblasts(OB) in favour of a microenvironment supporting 
malignant plasma cell growth and development. This is clinically noted in MGUS 
patients who had significantly reduced bone marrow density compared to normal 
controls with associated derangement of osteogenesis related cytokines[250]. Clinical 
Abnormalities in molecular pathways including the RANK/RANKL/OPG, TNF, Notch, 
Want, RUNX2 and EphrinB2/EphB4 have been shown to increase osteoclast activity 
while suppressing osteoblast activity in MM as detailed elsewhere. 
 
 
1.9.3 Renal Impairment (RI) 
 
Historically, renal impairment has been challenging to classify given the range of 
functional kidney functional damage at presentation. End-stage renal disease is likely 
most commonly seen secondary to MM and requires dialysis in about 1.5% patients 
[251]. A certain degree of Acute Kidney Injury(AKI) and Chronic Kidney Disease(CKD) 
is reported between 20-50% of patients with MM during the disease course[234, 252-
254]. A serum creatinine(Cr) of > 2mg/dl(173mol/L) or reduced creatinine clearance 
(CrCl) at <40ml/min is the usual cut off to detect renal impairment in MM patients[255] 
identifying 20% patients renally impaired when newly diagnosed with MM[254, 256]. 
 
CrCl estimation is usually advised using either the Modification of Diet in Renal 
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Disease(MRDR) or the Chronic Kidney Disease Epidemiology Collaboration(CKD-EPI) 
formulae, with a preference towards the latter given its higher sensitivity towards the 
estimation of GFR[257]. Estimated GFR(eGFR)  is known to be confounded by 
individual factors such as changes in body mass, diet and proximal tubule dysfunction. 
The potential use of Cr and serum cystatin would be superior in estimating GFR along 
with the added advantage of estimation of MM disease burden[258]. Further, AKI is 
more common than CKD in newly diagnosed MM patients, and RIFLE(risk, injury, 




1.9.3.1 Pathogenesis – RI 
 
MM Monoclonal lights chains are freely filtered in the glomerulus. They are endo-
cytosed and catabolised in the proximal tubular cells. Overwhelming of this scavenging 
mechanism promotes the appearance of the light chains in the tubular fluid where they 
combine with Tamm-Horsfall (Uromodulin – a glycoprotein secreted by the medullary 
ascending loop of Henle)[260]. The interaction of complementary determining region 
of the light chains and discrete binding sites on uromodulin leads to the formation of 
casts and aggregates which in turn cause distal tubular obstruct-ion[261]. This upsets 
the usual ratio of kappa () to lambda () light chains from median 0.6(range 0.26-1.65) 
to 1.1(range 0.37-3.1)[262, 263]; burdening the reticulo-endothelial system for serum 
free light chains (sFLC) clearance. Another determinant of light chain cast formation 
would be the difference of Isoelectric point (Ipl) of the light chain potentially influencing 
the pattern of light chain deposition with higher Ipl’s associated with light chain 
deposition disease [264]. RI in this setting can be worsened by the simultaneous use 
of nephrotoxic drugs/dyes, hypercalcemia and dehydration[265].  light chains usually 
show a greater renal involvement with amyloid and renal damage while  light chains 
have been a more frequent cause of light chain deposition disease (LCDD) and rare 
Fanconi’s syndrome[266, 267]. Kappa light chains have a higher propensity of liver 
deposition[268].
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2.0 Fig. 5  Overview of factors implicated in development of MM and treatment resistance
58 
 
2.1 Disease spectrum 
 
2.1.1 Monoclonal Gammopathy of Undetermined 
Significance(MGUS) 
 
It is widely accepted that MGUS precedes MM and exists in about 3 % of population 
over 50 years of age with increasing prevalence at 5.3% of those over 79 years of age 
and factors such as race(black population> white population> Asian population), sex 
(male >female), familial history and occupational risk[236, 269].  MGUS in itself is 
benign with presence of <=3g/dL serum M protein with <=10% bone marrow 
monoclonal plasma cells, no CRAB( C= hypercalcemia, R= renal impairment from 
Monoclonal protein (M), A = Anemia with disease-related Hb <10g/dL and B = bone 
involvement - Fractures/lytic lesions) features and no 'M' protein or only modest light 
chain in the urine[270, 271]. The risk of progression to MM is 10% at ten years and 36% 
at about 40 years from diagnosis(not accounting for death due to competing risk). The 
progression risk is higher in IgM MGUS versus non-IgM MGUS. This risk progressively 
worsens with the presence of risk features including an abnormal serum free light chain 
ration (sFLC) and high serum M protein. Given the potential risk of progression of 




2.1.2 Smouldering multiple myeloma(SMM): 
 
This biological state of MM spectrum of development is important to highlight given the 
increased potential of progression to symptomatic MM. Kyle et al. first successfully 
defined SMM in 6 patients analogous to smouldering acute leukaemia where bone 
marrow contains a higher proportion of blast cells; however, patients are typically 
asymptomatic for a prolonged duration of time. They further suggested a wait and 
watch approach towards management of SMM. Although newer studies show high-risk 
SMM with rapid progression to active MM within two years from diagnosis[273]. Hence 
early diagnosis, shorter follow up periods and proactive treatment of high-risk SMM is 





Currently, SMM is defined as the presence of serum M protein of >=3g/dL with 10% to 
60% clonal bone marrow PCs with no CRAB features or Myeloma defining event 
(MDE){ including: a) Bone marrow plasma cells [BMPC's], b) involved: uninvolved 
serum free light chain[sFLCs] >= 100, c) >1 magnetic resonance imaging[MRI] proven 
disease related lesion of the disease[274]. It is a distinct entity from MGUS given the 
higher potential to progress to active MM (50% progression at five years, 3% 
progression rate for the next five years and 1% stable progression rate from 10 years 
onwards). SMM increasingly recognizes higher risk dormant MM with the potential of 
transforming to active disease in 40% of patients with these features per year[275]. 




2.2 Diagnosis and risk stratification 
 
2.2.1 Revised diagnostic criteria 
 
Traditionally MM was diagnosed based on CRAB features along with 10% or more 
monoclonal plasma cells in the bone marrow. However, several studies identified high-
risk features (now termed MDE’s) which are associated with a high rate of progression 
from indolent disease to active MM[273, 276-279]. Further, improved sensitivity of 
detection of myelomatous bone lesions has led to the inclusion of more advanced 
imaging modalities to be acceptable in the workup of MM as mentioned below 
 
a) Clonal BM plasma cells >=10% or biopsy-proven bony or extramedullary 
plasmacytoma with one or more of the following: 
 
i) Hypercalcemia – Serum calcium > 2.75mmol/l(>11mg/dl) by 0.25mmol/l 
(>1mg/dl) : ‘C’ 
ii) Renal dysfunction: Serum creatinine > 177mol/l(>2mg/dl) or creatinine 
clearance < 40ml/min: ‘R’ 
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iii) Anemia:  Hb value <100g/l(10g/dL) or >20g/l(2g/dL) below lower limit of 
normal : ‘A’ 
iv) Bone lesion: >= 1 osteolytic lesion on Skeletal survey, CT, PET-CT: ‘B’ 
 
b) >=1 of the following biomarkers: 
 
i) Involved: uninvolved sFLC ratio >=100 
ii) >=1 focal lesion on MRI scans ( lesion to be >= 5mm in  diameter) 
 
*International Myeloma Working Group Diagnostic Criteria for Multiple Myeloma 
(IMWG) criteria[280] 
 
The CRAB features must be MM associated, and other causes of the same should be 
excluded. The renal disease of MM should be biopsy proven if causes other than light 
chain cast nephropathy could be implicated for the cause of renal dysfunction, 
including light chain deposition disease, amyloid light chain amyloidosis and 
membranoproliferative glomerulonephritis which can occur with M protein and would 
require disease-specific management approach[280, 281] 
 
Solitary plasmacytoma’s with normal bone marrow findings and no disease-related 




2.2.2 Disease staging and assessment for risk 
 
Given the disease heterogeneity, it is vital to risk stratify MM patients for 
prognostication. Two widely used risk stratification scores are used, the Durie and 
Salmon system(DSS) and the International Staging System(ISS). Both systems 







2.2.2.1 Durie Salmon Staging(DSS)(table 3) 
 
DSS was introduced in 1975 estimated MM tumour burden based upon the Hb, calcium 
and M protein levels in the patient’s serum along with MM-related bone lesions. The 
score obtained from these measurements qualified patients into Stage I -low(<0.6x1012 
/m2), Stage III - high(1.2x1012  /m2) and stage II - intermediate(in between stage I and 
III) tumour mass. Further subclassification into Group A or B was based on serum 
creatinine of < 2 or > 2mg/100ml respectively. The system provides useful initial 
assessment and post-therapy response by evaluating a change in tumor burden (table 
3). 
 
However, the drawback of this system is subjectivity in evaluating the lytic lesions[282]. 
It is uncertain how independently prognostic is the number of lytic lesions with the 
disease as studies evaluating the same are limited. Further, the system primarily 
considers the host disease burden for assessing the tumour burden. With growing 
applicability of knowledge of disease biology and understanding of MM being a 
heterogeneous disease of clonal population, modest estimation of tumour disease 
burden would underappreciate the high-risk features associated with the tumour 
biology itself, particularly in high-risk SMM. With newer MM therapies, where the 
disease ‘bulk’ might be reduced, the remaining resistant clonal MM plasma cell would 
be challenging to risk stratify using this system of classification. 
 
Stage Criteria Tumor mass 
I All criteria’s: 
Hb >10g/dL(100g/L) 
Normal Calcium or < 12mg/dL (3mmol/L) 
IgG<5g/dL    IgA ,3g/dL 
No or single bone lesion 
Monoclonal urinary protein > 12g/24hours 
Low tumour mass 
<0.6x1012 /m2 
II Between stages I and II Intermediate tumour 
mass 
III Any of the following: 
Hb < 8.5g/dL(85g/L) 
Calcium > 12mg/dL (3mmol/L) 




IgG > 7 g/dL(466.9mol/l), IgA > 5g/dL(333.6mol/l) 
Monoclonal urinary protein > 12g/24h 
Multiple osteolytic lesions, fractures 
Subclass          A – Creatinine <2mg/dL(<177mol/l) 
B – Creatinine >=2mg/dL(>=177mol/l) 
Table 3: DSS staging system 
 
 
2.2.2.2 Durie Salmon Staging(DSS) plus staging(table 4) 
 
The system improved upon observer bias by including advanced imaging including 
MRI/PET scans to their previous criteria’s. DSS plus also aimed to prevent 
unnecessary treatment of MGUS and early stage smouldering MM while identifying 
high-risk disease subgroups( > 20 bone lesions or extramedullary disease) and 
accurately staging oligosecretory/non-secretory MM [283]. 
 






Number of lesions 
I B  I   0-4 
II A or B  II 5-20 
III A or B  III > 20 
B: Creatinine > 2mg/dL and/or Extramedullary disease(EMD) on PET or MRI 
Table 4: Durie Salmon Staging plus staging 
 
 
2.2.2.3 International Staging system(ISS)(table 5) 
 
Is a simplified risk stratification system utilizing two variables, serum 
2microglobulin(2M) and serum albumin. 2M is reflective of tumour burden along 
with renal function[284, 285]. Serum albumin production by the liver is likely affected 
by the effects  of increased IL-6 associated with the bone marrow microenvironment in 
MM patients. on liver[285]. This system segregates patients based on the levels of both 
of these variables; the normal value is associated with better patient prognosis. 
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Table 5: ISS staging system (2005) [284] 
 
2.2.2.4 Revised International Staging System (R-ISS)(table 6) 
 
Cytogenetic abnormalities have significant prognostic implications for patients with MM. 
As MM is a hedisease, delineating it merely by using biochemical measures would be 
inadequate when individualizing patient treatment. Several studies identified poor 
overall survival (OS) in MM patients harbouring del17p, t(4;14) along with a high 
Lactate dehydrogenase (LDH)[286-288] at diagnosis. This 5% cohort of of MM patients 
at diagnosis respond poorly to treatment with early relapse and mortality within two 
years of diagnosis. ISS was therefore revised to increase the sensitivity of this  
prognostication index.[107, 289, 290] 
Table 6: Revised ISS[107] 
 
Stage Criteria 
I Serum 2M <3.5mg/l(296.8nmol/L) and serum albumin >= 
3.5g/dl(35g/L) 
II Neither stage  I or III 
III Serum 2M >= 5.5mg/l(466.49 nmol/L) 
Prognostic factor                                                          Criteria 
ISS Stage  
I Serum β2-microglobulin < 3.5 mg/L, serum albumin ≥ 3.5 g/dL 
II Not ISS stage I or III 
III Serum β2-microglobulin ≥ 5.5 mg/L 
Cytogenetics by interphase FISH (iFISH) 
High risk Presence of del(17p) and/or translocation t(4;14) and/or translocation 
t(14;16) 
Standard risk No high - risk CA 
LDH 
Normal Serum LDH < the upper limit of normal 
High Serum LDH> the upper limit of normal 
R-ISS stage 
I ISS stage I and standard-risk CA by iFISH and normal LDH 
II Not R-ISS stage I or III 
III ISS stage III and either high-risk CA by iFISH or high LDH 
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2.3 Response assessment 
 
Quality and Duration of responses have significantly improved with newer drug 
combinations and high-dose therapy with autologous stem cell transplantation 
(HDT/ASCT). Patients achieving IMWG defined complete remission(CR)(Table. 7) 
have been shown to relapse slowly and have significantly longer OS[291].  Response 
categorization to chemotherapy in MM has incorporated investigative methods with a 
sensitivity of detecting 1 MMPC in 105 -6 cells in the bone marrow. The disease burden 
in this context is called minimal residual disease (MRD).   
 
The international myeloma workgroup(IMWG) have sub-divided the depth of response 
achieved based upon newer methodology with higher sensitivity including multicolour 
flow cytometry, Ig Allele–specific oligonucleotide–based quantitative polymerase chain 
reaction(ASO-PCR), next-generation sequencing(NGS) and MRI/PET-CT[292]. These 
advanced modalities detect MRD(table 7b) which is undetectable by conventional 
methods where the maximal attainable response is stringent complete response 
sCR(table.7a). The rationale for assessing MRD is due to the evidence of prolonged 
PFS for patients in CR who are MRD negative compared to those who are in CR but 
MRD positive. MRD negativity on long-term follow up has shown to be relapse free up 
to 10 years, identifying possible ‘cured’ population of MM patients who enjoy a longer 
PFS and OS [293, 294].  
 
Utilization of MRD in routine clinical practice still has a few hurdles to cross. Being 
specialized, these diagnostic tests are not available worldwide. MRD is a surrogate 
marker for OS and can be used to compare treatment options. However standard-
ization of interpretation of MRD results in the context of timing and frequency of repeat 
results, and its optimum utilization in applying to different clinical contexts including 
high-risk disease, appropriate timing of re-commencing/changing treatment, the 








Response subcategory                   Response criteria 
mCR CR & ASO-PCR -ve’ sensitivity 105 
iCR sCR & -ve BM aberrant PC’s by MPF(>4 colours) on analysing 1x106 
BM cells  
sCR CR + Normal FLC & -ve clonal PC by IHC or 2-4 colour flowcytometry 
CR -ve urine and serum IF and resolution of soft tissue plasmacytoma 
and <=5% BMPC’s  
 (VGPR) M protein in serum and urine by +IF & - SPEP or >= 90% reduction 
of serum M protein + urine M protein<100mg/24hrs 
PR >=50% reduction of serum M protein and reduction in 24hrs urinary 
M protein by >=90% to <200mg/24hrs. 
If non/oligosecretory MM then >50% reduction in PC’s when baseline 
PC’s were >=30% 
Along with above if plasmacytoma noted at diagnosis, >= 50% 
reduction in size is required 
PD Increase of 25% from lowest confirmed response value for: 
a) Serum M protein (absolute increase must be >=0.5g/dL 
b) Serum M protein increase>=1g/dL if the lowest M component 
was >=5g/dL  
c) U M protein(absolute increase to be >=200mg/24hrs) 
Table 7a: Adapted from ESMO 2017 guidelines[274].  
mCR: molecular complete response; iCR: immunophenotypic CR; sCR: stringent complete 
response; CR: complete response; VGPR: very good partial response; PR: partial response; 
PD: progressive disease; -ve: negative ASO-PCR: allele-specific polymerase chain reaction; 
MPF: multiparametric flowcytometry; FLC: free light chain ratio; IHC: immunohistochemistry; 












Response subcategory               Response criteria 
Sustained MRD -ve MRD -ve In BM(NGF/NGS) & by imaging confirmed a year apart. 
Evaluate to specify the duration of MRD -ve.  
Flow MRD -ve No monoclonal PC by NGFC on BMA using Euroflow standard 
operation procedure for MRD detection in MM( or an equivalent 
validated method) with a minimum sensitivity of 1 in 105 nucleated 
cell or higher 
Sequencing MRD -ve No clonal PC by NGS on BMA where the presence of a clone is 
defined as less than two identical sequencing reads obtained after 
DNA sequencing of BMA using the Lymphosight platform(or 
validated equivalent method) with a minimum sensitivity of 1 in 105 
nucleated cell or higher 
Imaging + MRD -ve MRD -ve as per NGFC or NGS + PET-CT disappearance of tracer 
uptake from baseline or decrease to< mediastinal blood pool SUV 
or decrease to less than that of surrounding tissue 
Table 7b: Adapted from ESMO guidelines 2017[274] 
MRD: minimal residual disease; -ve: negative; NGF: next generation flowcytometry; NGS: 
next-generation sequencing; NGFC: next generation flow cytometry; BMA: bone marrow 
















2.4 Treatment  
 
Significant advances with the introduction of newer and targeted therapeutics have 
increased treatment options for MM patients. As multiple myeloma is still incurable, 
primary treatment objective is to induce the best possible response for a prolonged 
duration with minimal toxicities. To accomplish this, synergistic drug combinations are 
widely used in the treatment of MM.  
 
 
2.4.1 Treatment drugs 
 
2.4.1.1 Proteasome inhibitor(PI) 
 
2.4.1.2. Bortezomib (First generation) 
 
Bortezomib is a specific 26S proteasome inhibitor which forms are a reversible but 
strong covalent bond between dipeptide boronic acid moiety and threonine proteases’ 
20s subunit. It has several important mechanisms of action including: 
 
1. Mitochondrial dysfunction; cytochrome c release; reactive oxygen species 
production 
2. Modulate JNK kinase activity causing enhanced caspase 3 and 8 activation 
3.  Immune-mediated cell damage 
4.  Dysregulation of cellular stress response including NF-kB 
5.  Derangement of apoptotic protein including  unfolded protein response(UPR) 
6.  Elevate p53 levels 
7.  Reduces cytokine production 
8.   Impairment of transcriptional factors 
9.  Cell cycle proteins dysfunction 
 
Owing to a multitude of targets and synergism with a lower dose of steroids and other 
newer targeted agents, it is widely used in combination for all disease treatment stages 
as a single agent or as drug combinations for treatment of MM[296]. Significant dose-
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limiting side effects include motor and sensory neuropathy, cytopenia/s, 
gastrointestinal symptoms including nausea, vomiting, diarrhoea[178].   
 
 
2.4.1.3 Second generation proteasome inhibitor - Carfilzomib 
 
Carfilzomib is an epoxyketone which irreversibly binds to N- terminal threonine 
residues of the catalytic proteasomal subunits with prolonged proteasome inhibition as 
compared to the reversible boronic acid binders (Bortezomib and Ixazomib). It received 
approval in Europe for use in  MM patients who received 1-3 prior treatment lines in 
2015. Dimopoulos et al reported a median progression-free survival of 18.7 months( 95% 
CI 15.6 - not estimable)  versus 9.4 months( 8.4 - 10.4) In patients receiving Carfilzomib 
with dexamethasone(KD)  versus bortezomib with dexa-methasone respectively in the 
interim analysis[HR 0.53(95% CI 0.44-0.65);p<0.0001)] of ENDEAVOR study. 
Common side effects In Carfilzomib group anemia (14%), hypertension(9%), 
thrombocytopenia(8%) and pneumonia(32%) [297]. The Aspire study compared 
Carfilzomib lenalidomide and dexamethasone (KRD) to lenalidomide and 
dexamethasone alone Iand noted significantly improved PFS  of 26.3 vs 17.6 months 
in the respective study arms(p=.0001). Comparable grade 3 or higher adverse events 
were reported in either of the arms, and increasing trend of treatment discontinuation 
was noted in the lenalidomide and dexamethasone[298]. 
 
 
2.4.1.4 Ixazomib (MLN9708) 
 
Ixazomib Is a second-generation proteasome inhibitor with boron containing 
proteasome inhibitor reactivity. It has a short 20s proteasome dissociation T1/2 likely 
improving its tissue distribution. In preclinical models, it showed superior antitumor 
activity as compared to bortezomib due to improved pharmacokinetics, tolerability and 
bioavailability in comparison to bortezomib[299]. The anti-tumour activity of ixaz-omib 
was further replicated in mouse models of B-cell and plasma cell malignancies leading 
to initial phase trials in relapsed/refractory MM[300-303].  
The Tourmaline-MM1 Study was a double-blinded placebo-controlled trial for 722 
relapsed and or refractory impatient who received either ixazomib with lenalidomide 
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and dexamethasone(treatment)  or placebo with lenalidomide and dexametha-
sone(placebo) arm. An overall response rate(ORR)  of  78% vs  72% were noted in the 
treatment versus placebo A group with a more prolonged median progression-free 
survival(PFS) of 20.6 months versus 14.7 months (p=0.01) reported in the two groups 
respectively. Similar rates of adverse events were noted between the two groups. 
Grade 3 thrombocytopenia(12%), rash(36%) and low grade gastro-intestinal adverse 
events were reported in the treatment group[304].  
 
 




Thalidomide was initially marketed as a sedative and anti-antiemetic during pregnancy 
and subsequent withdrawal due to teratogenicity in newborn babies. Thalidomide 
belongs to the immunomodulatory(IMID)  group of drugs with strong anti-myeloma 
activity.  It is a synthetic glutamic acid product with poor water solubility. Some of the 
important mechanisms of action include[305, 306]: 
 
1. Anti-angiogenic activity secondary to inhibition of cytokines such as basic 
fibroblast growth factor(BFGF) 
2.  Immunomodulatory effects 
3.  Inhibition of NF-kB signalling inducing apoptosis via caspase-8 / death receptor 
pathway 
4. Inhibition of Cereblon(cerebral protein with Ion protease) and E3 ubiquitin ligase  
complex – Speculated role in teratogenicity  
 
Rajkumar et al. investigated thalidomide in combination with dexamethasone 
(treatment) vs dexamethasone alone(control)  when treatment options for newly diag-
nosed MM patients were limited. This phase 3 randomised trial reported higher 
response rates in the treatment versus control arm ( 63% vs 41%; P=0.017). Grade 3  
deep vein thromboembolism(DVT), rash, cardiac adverse events and neuropathy were 
significantly higher in the treatment group[307]. Significantly higher overall response 
rate(ORR)  of 63% vs 46%(P<0.001) and the median time to progression (TTP) 22.6 
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versus 6 months(p<0.001)  were reported in another multicenter random-ized double-
blind phase III comparing treatment versus control arm as in the previous study[308]. 
Its side effect profile includes peripheral neuropathy which is exacerbated when used 
in combination with bortezomib with increased incidence on higher thalidomide 
dose[309]. There is an increased risk of venous thromboembolism, mainly when used 
in combination with high dose steroids. It is now used less preferably when compared 
to the newer generation of IMID’s due to better treatment tolerability and response[309]. 
Increased risk of arrhythmias has also been reported in the OPTIMUM study as 
compared to Dexamethasone[310]. 
 
 
2.4.2.2 Lenalidomide  
 
Lenalidomide an analogue of thalidomide with lesser toxicity likely due to its structural 
difference from thalidomide by single carbonyl ring and an amino acid group. It is an 
anti-proliferative immunomodulator which induces apoptosis and stimulates T and NK 
disrupting the MM - microenvironment crosstalk [311, 312].  
 
MM 009  and 010 studies showed the superiority of lenalidomide in combination with 
dexamethasone(treatment) when compared to dexamethasone alone(control). The 
MM009 study showed significantly higher response rates with a median time to 
progression of 11.1 months vs 4.7 months(p< 0.001) and median overall survival 
different of 29.6 vs 20.2 months(p<.001) between the treatment and the control arms 
respectively. MM 010 study also reported along longer time to progression, higher 
response rates and significantly improved OS between the treatment and the control 
arms. Common side effects included neutropenia, thrombocytopenia and increased 
risk of venous thromboembolism in the treatment group.  
 
Lenalidomide is widely used as an induction agent given higher response rates in 
combination with proteasome inhibitors(transplant eligible) or combination with 
dexamethasone in transplant ineligible/frail elderly patient. It is also used for 
maintenance in patients with a higher risk of relapse. 
 





Pomalidomide is a thalidomide analogue which has significant anti-MM activity. Like 
other IMIDS  it is an immunomodulatory agent which binds cereblon component of E3 
ubiquitin ligase complex. This impacts B and T cell development due to ubiquination 
and subsequent proteasomal degradation of downstream transcription factors Ikaros 
and Aiolos. It is also known to enhance NK and T cell activation causing antibody-
dependent cellular cytotoxicity[313, 314]. 
 
 Pomalidomide was approved for use in relapsed / treatment refractory MM patients in 
Europe based on evidence from MM-003 trial. This multicentre open-
label,  randomised phase III trial included patients refractory or relapsed and refractory 
to minimally two previous lines of treatment including lenalidomide and bortezomib. 
The treatment arm received pomalidomide with low-dose dexamethasone and the 
control arm received high-dose dexamethasone alone. Median PFS after treatment on 
was 4 months( 95% CI 3.6-4.7)  versus 1.9 months( 95% CI 1.9-2.0). 








Daratumumab is an anti-CD 38 IgG1k  human monoclonal antibody. CD38 is 
selectively highly expressed on malignant plasma cells, with limited expression on 
other hematopoietic cells. Its tumoricidal effect is mediated by antibody dependent cell-
mediated cytotoxicity, complement dependent cytotoxicity and antibody-dependent 
cellular phagocytosis. It was first approved as monotherapy based upon the results of 
MMY2002, and GEN501 studies, where a significant proportion of patients showed a 
clinical response to single-agent daratumumab after having relapsed or been refractory 
to at least two or more prior treatments including PI and IMIDs[316, 317].   
 
MMY3003 and MMY3004 are important trials that evaluated daratumumab in 
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combination with either lenalidomide with low-dose dexamethasone or bortezomib with 
low-dose dexamethasone with comparative arms of lenalidomide with low-dose 
dexamethasone and bortezomib with low-dose dexamethasone respectively. Patient 
populations in both studies had been previously heavily treated and relapsed on 
several lines of therapy. The MMY3003 showed a PFS advantage of 83.2% vs 60.1% 
in daratumumab group vs the control group at 12 months respectively. Higher response 
rates were also noted in the daratumumab group versus the control group ( 92.9% vs 
76.4%; p<0.001). Cytopenias were the most common side effects other than grade 1 
to 2 infusion-related reactions in 48%[318]. The MMY3004 reported a 12-month PFS 
of 60.7% in the daratumumab arm versus 26.9% in the control arm. The median PFS 
was 7.2 months in the control arm vs not reached after a median follow-up of 7.4 
months. Higher rates of responses were noted in the daratumumab arm vs the control 






Elotuzumab recombinant monoclonal immunoglobulin G1(IgG1) antibody which 
selectively binds its epitope located within C2 domain of anti-signalling lymphocyte 
activation molecule family 7 (SLAMF7). This family of receptors have an imminent role 
in regulating immune responses. MM plasma cells universally express high levels of 
SLAMF7 along with some expression reported on NK cells, all B cells and activated T 
cells. The binding of elotuzumab to SLAMF7 on MM signals CD16 receptor-driven NK 
cell crosslink to the plasma cell activating ADCC  causing targeted MM plasma cell 
death. However, functional NK cells are required for elotuzumab mediated ADCC[320, 
321]. 
 
ELOQUENT 2  Phase III randomized clinical trial assessed the efficacy of elotuzumab 
in combination with lenalidomide and dexamethasone and (elotuzu-mab)  purchase 
lenalidomide and dexamethasone alone(control) in patients who had a documented 
relapse after one two three lines of previous therapies. The rationale for this 
combination being lenalidomide role in upregulating NK cells. The median PFS in the 
elotuzumab group was 19.4 months versus 14.9 months in the control group which 
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was statistically significant(p<0.001). Significantly higher response rates were also 
noted at 79%(elotuzumab) vs 66%(control)(P<0.001). Compared to daratumumab 
lesser infusion-related grade one or two reactions were reported(10%)[322].  
 
ELOQUENT 3 study evaluated a combination of elotuzumab pomalidomide and 
dexamethasone(elotuzumab) versus pomalidomide and dexamethasone(control) 
alone in patients previously refractory to a PI and lenalidomide. The primary endpoint 
of the study was to assess PFS which was 10.3 months in the elotuzumab group 
versus 4.7 months in the control group(p=0.008). Elotuzumab group saw double the 
overall response rate as compared to the control group(53% vs 26%). The toxicity 
profile was favourable in the elotuzumab group with a lesser number of grade 3 or 4 
neutropenia and anaemia as compared to the control group.  The study highlighted a 
significantly lower risk of progression or death in this cohort of patients[323]. 
 
 




Panobinostat is a histone deacetylase(HDAC) inhibitor that augments processes 
regulated by histone acetylation. Preclinical studies with xenograft models showed 
increased anti-tumor potential in MM of panobinostat in combination with bortezomib 
and dexamethasone[324]. Phase III Panorama trial results using panobinostat in 
combination with bortezomib and dexamethasone in comparison to dexamethasone 
and bortezomib for patients with relapsed or refractory and relapsed MM. There was a 
modest 4-month survival advantage with the triplet with significant grade 3-4 
gastrointestinal toxicity, thrombocytopenia and fatigue[325, 326]. Panobinostat’s use 
based upon the trial results would require significant deliberation where the benefit of 







2.4.5 High dose therapy(HDT)/Autologous stem cell transplantation 
(ASCT)  
 
HDT with ASCT has been a crucial therapeutic milestone for patients with multiple 
myeloma where the median survival of patients with conventional chemotherapeutic 
was in the range of about 3.5 years[327-329]. The role of transplantation before the 
advent of novel agents was vital for inducing prolonged remission and improving OS 
[Attal et al. showed an overall estimated survival of 52% at five years post ASCT 
compared to 12% with conventional chemotherapy(p=0.03)][330]. Novel agents have 
not only improved outcomes as an induction regimen compared to conventional 
regimens but have also shown similar survival trends as compared to ASCT  and have 
opened options for delayed transplantation[331]. Further triplet combinations of PI and 
IMIDs with steroids are preferred given a higher frequency of more profound response 
and PFS advantage[332, 333].  
 
However, there is a definite advantage of ASCT over either standard/conventional 
chemotherapeutic approaches separately and should be considered for all newly 
diagnosed MM patients transplant eligible. This has been shown is a recent 
metanalysis examining the role of ASCT in the context of novel agent use. This study 
Showed that high dose melphalan followed by autologous stem cell transplant was 
associated with superior PFS when compared to chemotherapy alone. They further 
showed superior PFS with either tandem ASCT or ASCT with VRD  when compared 
to ASCT alone. The study more importantly reflects higher complete remission rates 
in the ASCT group[334]. This is important given no significant increase in treatment-
related mortality ASCT group and particularly considering long-term effects and cost 
of continued/recurrent chemotherapy. Role of upfront tandem ASCT is likely more 
important in the context of high-risk cytogenetics subgroup given suboptimal 
treatment response in this patient subgroup compared to standard risk group even in 








2.4.5 Conventional chemotherapy 
 
MP(melphalan, prednisolone), M-2 protocol (melphalan with cyclophosphamide, 
prednisolone, carmustine and vincristine) and VCMP( vincristine, cyclophosphamide, 
melphalan, prednisolone) are some of the historical treatment options used in MM. 
These treatment options had significant toxicity profile including high steroid-related 
cushingoid effects, no significant benefit for bony disease and further, in some 
instances such as MP, incremental bone marrow failure rates. VAD(vincristine, 
doxorubicin, dexamethasone), perhaps is the most reasonable for usage due to the 
fast response rates as induction before HDT/SCT. The OS benefit of either combination 
therapy(COT) or MP based was found to be similar at 29 months, highlighting a lack 
of incremental response with either approach compared to the use of newer generation 
of targeted therapies. In relapsed MM, the prognosis was dismal if patients relapsed 
on CCP usage with VAD and cyclophosphamide( hyper-CVAD)[337]. Use of MP might 
still be appropriate in the elderly patient with resistant disease/inadequate response to 
newer therapeutic combinations or limiting toxicity profiles, where some disease 
















2.5 Treatment strategies 
 
2.5.1 Newly Diagnosed MM  
 
2.5.1.1 Transplant eligible/<65 years(Fig.6) 
 
Current treatment approach for patients under 65 years of age  with good performance 
status should be given  4 to 6 cycles of usually triplet combination induction therapy to 
achieve deep response followed by  HDT/conditioning with Melphalan 200mg/m2 or 
140mg/m2(older patients or renal impairment[338]) and ASCT involving by re-
introduction of at least 2 million peripheral blood progenitors(CD34+) cells[339]. 
Subsequently, IMID based maintenance therapy should be considered. Allogeneic 
transplantation is avoided due to significant toxicity and prolonged need for 
immunosuppression and higher mortality risk.   
 
 
2.5.1.2 Transplant ineligible/>65 years(Fig.6) 
 
A transplant is a considerable option for non-frail, older patients with younger biological 
age and no significant comorbidities[340]. Preferable options include VMP or Rd. until 
disease progression. Recently bortezomib is also used in combination with Rd given a 
significant improvement of OS in this patient sub-group. In the case of pre-existing 





Fig6: Treatment pathway for newly diagnosed MM patient[339] 
VRD- bortezomib, revlimid, dexamethasone; VTD-bortezomib, thalidomide, dexamethasone; VCD-
bortezomib, cyclophosphamide, dexamethasone; PAD- bortezomib, doxorubicin, dexamethasone; 
VMP- bortezomib, melphalan, prednisolone; RD- revlimid, dexamethasone; MPT- melphalan, 
prednisolone, thalidomide; CTD- cyclophosphamide, thalidomide, dexamethasone; MP- melphalan, 
prednisolone; BP- bendamustine, prednisolone 
 
 
2.5.1.3 Relapse/refractory MM (fig.7a and b) 
 
Based on the induction regimen, treatment options on relapse should be chosen from 
an alternative drug group in combination with steroids (fig.7). Relapse management 
varies based on previous treatment exposure, drug resistance and the number of 
treatment cycles. There is a significant role of newer PI’s and mAb-based approach in 
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this patient population as the disease usually becomes progressively resistant. The 




Fig7a: Treatment pathway for relapsed MM patients[339]  
VRD- bortezomib, revlimid, dexamethasone; VTD- bortezomib, thalidomide, dexamethasone; VCD-
bortezomib, cyclophosphamide, dexamethasone; PAD- bortezomib, doxorubicin, dexamethasone; RD- 
revlimid, dexamethasone; DaraVD- bortezomib, daratumumab, dexamethasone; PanoVD- panobinostat, 
bortezomib, dexamethasone; EloVD- elotuzumab, bortezomib, dexamethasone; KRd- carfilzomib, 
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Fig7b: Treatment options after 2nd relapse[339] 
Cyclo- cyclophosphamide; Ixa- Ixazomib; Bor- Bortezomib; Dara- Daratumumab; Elo- 




Solitary plasmacytoma in the absence of systemic involvement with MM can be 
managed with localized radiotherapy. Careful monitoring is required to assess for 
systemic disease progression[339]. 
 
2.5.3 Supportive care: 
 
80% of MM patients have skeletal involvement while about 60% of these will 
experience a disease related fracture during their disease course. There is increased 
osteoclastogenesis and reduced osteoblast activity in MM. Along with systemic 
treatment, administration of bisphosphonates has strong evidence in MM patients, 
particularly with lytic lesions. Either monthly pamidronate or Zoledronic acid can be 
given up to two years. A dental review is recommended before bisphosphonate usage 
owing to the risk of osteonecrosis along with monitoring of the renal function before 
bisphosphonate usage[339, 341].  
 










2.5.4 Emergency care: 
 
Cord compression would be an acute emergency for patients with involvement of 
vertebral column. Orthopaedic decompression may be needed along with localized 
radiotherapy with high dose dexamethasone which should be promptly initiated on 
diagnosis[339]. Tumour lysis syndrome should be pre-empted in patients with 
significant disease burden/renal impairment and managed with adequate hydration 





























3.0 Aims of thesis 
 
I) Identification of molecular target for aurora kinases and  




II) Study of natural history of 17p loss in MM: 
 
IIa) De-novo  
               


































 3.1 Aim I) Identification of molecular targets of aurora 



















Aberrant expression of proteins involved in cell division is a constant feature in multiple 
myeloma (MM), especially in high risk disease. Aurora kinases are proteins that are 
important mediators of cell division whose levels are up regulated in MM.  Functional 
loss of Aurora kinases results in genetic instability and dysregulated division leading 
to cellular aneuploidy and growth arrest. We investigated the role of Aurora kinase 
inhibition in MM, using a small molecule inhibitor A1014907.  
 
Low nanomolar A1014907 concentrations induced aneuploidy in all MM cell lines 
across various cytogenetic abnormalities by inhibiting Aurora Kinases A and/or B. 
However, A1014907 induced more pronounced dose dependent apoptosis in cell lines 
with t(4;14) translocation. t(4;14) translocation is observed in about 20 % of patients 
with MM with two-thirds of these demonstrating constitutively activate FGFR3. Further 
investigation on the mechanism of action of A1014907 revealed potent FGFR3 
pathway inhibition in sensitive cell lines as demonstrated by inhibition of p-PLC, p-
Stat3 and p-PKC levels.  
 
Examining the effect of A1014907 on patient cells in vitro also showed preferential 
apoptotic induction by the drug in patients with t(4;14) translocation. Thus, our results 
showed that aurora kinase inhibition led to cell cycle arrest and aneuploidy with 
minimal apoptosis whereas inhibiting both aurora kinase and FGFR3 activity induced 
potent apoptosis in MM cells. Finally, combining A101 with dexamethasone showed 
potent synergy in inducing cytotoxicity in both the sensitive and resistant MM cell lines. 
Our results warrant clinical evaluation of A1014907 in combination with 























Aurora kinase A – blue 
Aurora kinase B - Red 
3.1.2 Fig. 8 Progression of cell through G2/M phase and Aurora Kinases expression[1] 
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3.1.3 Materials and Methods 
 
3.1.3.1.1 Cell lines 
 
MM cell lines MM1S, MM1R, RPMI8226, OPM2 and U266, were kindly provided by 
DrJonathan Keats (TGen, Phoenix, AZ). Kas6 was kindly provided by Dr John Lust 
(Mayo Clinic, Rochester, MN). KMS11, KMS18, KMS28BM, KMS34, LP1, OPM1, JIM2, 
JIM3 and INA6 were kindly provided by Dr Leif Bergsagel (Mayo Clinic, Scottsdale, 
AZ). H929 was purchased from ATCC (Manassas, VA, USA) and DOX40 was kindly 
provided by Dr William Dalton (Moffitt Cancer Center, Tampa, FL, USA). ALMC1, 
ANBL6 and KP6 were kindly provided by Dr Diane Jelinek (Mayo Clinic, Rochester, 
MN). 
 
All cell lines except Kas6, KP6, ANBL6, ALMC1 and INA6 were cultured in RPMI 1640 
media (Mediatech Inc., Manassas, VA) containing 2 mM L-glutamine (Invitrogen, 
Grand Island, NY), 100 U/mL penicillin, 100 μg/mL streptomycin and 10% foetal bovine 
serum (Mediatech, Inc.). Kas6 and INA6 were cultured in same media but in the 
presence of 4 ng/mL of IL6 and 1 ng/ml IL6 respectively (R&D Systems, Inc., 
Minneapolis, MN). ALMC1, ANBL6 and KP6 were cultured in IMDM media (Invitrogen) 
containing 2mM L-glutamine (Invitrogen), 100 U/ml penicillin, 100 μg/mL streptomycin, 




3.1.3.1.2  Bone marrow aspirate  
 
Bone marrow aspirates were obtained from MM patients after informed consent under 
a protocol approved by the Mayo Clinic Institutional Review Board in adherence with 
the Declaration of Helsinki. CLL B-cells were obtained after informed consent under a 
protocol approved by the Mayo Clinic Institutional Review Board in adherence with the 
Declaration of Helsinki. 
 
Bone marrow (BM) aspirates from patients with MM were obtained after informed 
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consent under a protocol reviewed and approved by the Mayo Foundation Institutional 




3.1.3.1.3 Bone marrow aspirate preparation 
 
Bone marrow aspirate samples were lysed using ACK lysis buffer solution containing 
NH4Cl (8,024mg/l), KHCO3 (1,001mg/l) and EDTA Na2·2H2O (3.722 mg/l) for the 
lysing of red blood cells. 
 
Procedure: Lysis reagent was prepared as per manufacture’s protocol. 
All reagents of the lysis buffer mentioned above were dissolved in 850 mL of H2O and 
pH maintained between 7.2–7.4. Further 1litre of H2O was added for completion of 
lysis reagent. 
 
1. Fresh blood undergoes cytospin and then supranatant discarded 
2. An equivalent volume of ACK lysing buffer was added to the pellet remaining 
with care to keep similar volume of buffer to the pellet the remaining pellet. 
3. Gently shake the tube for 30-60 seconds to resuspend the pellet 
4. Fill tube with medium that does not contain serum and centrifuge. 
5. Again remove supernatant and retain pellet. 
6. This process can be repeated one more time if necessary. 
7. Proceed with normal cell protocol. 
 
The lysed samples further underwent CD138 antibody conjugation to magnetic beads 
using RoboSep (StemCell Technologies, Vancouver, BC, Canada) for separation of 
CD138+ MM cells. The isolated MM cells were checked for purity using a slide-based 
method to confirm more than 95% purity. MM cells were placed in medium A for use in 
the respective assays. For the generation of bone marrow stromal cells (BMSCs), 
CD138-negative MNCs were placed in 25-mm2 culture flasks in RPMI 1640 medium 





BM stromal cells (BMSCs) and coculture Freshly obtained BM aspirates were 
subjected to Ficoll–Paque gradient separation to isolate mononuclear cells (MNCs). 
These cells were placed in 25 mm2 culture flasks in RPMI-1640 media. Once the 





A1014907 was synthesized and provided by Abbott Laboratories Ltd under a Material 
Transfer Agreement (MTA). Stock solutions were made in DMSO, diluted in RPMI-1640 
and subsequently stored at −20° C. The diluted A1014901 was subsequently used for 
all experiments. Drug dilutions were made using the equation M1V1 = M2V2 
 
 
3.1.3.3 Cell Viability Assay 
 
Colorimetric assays were also performed to assay cell viability in the presence of 
A1014907. 4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide (MTT) was 
utilized to assess for viable cells as a percentage of control. Cells from individual cell 
lines were plated in the 96 well plates at a count of 20,000 cells in 100l of conditioned 
media (RPMI-1640 containing 10% Fetal bovine serum, 100u/ml penicillin and 
100mg/ml of streptomycin) with varied concentrations of A1014907 for 72-hour. In the 
last four hours of the 72 hours, all wells containing cells were pulsed with 10 μL of 5 
mg/mL 3 MTT. The 96-well plates were incubated at 37°C away from light for 4 hours, 
followed by addition of 100 μL isopropanol that contained 0.04 HCl. Absorbance 
readings at a wavelength of 570 nm (with correction using readings at 630 nm) were 
taken on a spectrophotometer (Molecular Devices, Sunnyvale, CA). Each experiment 








3.1.3.4 Cell proliferation assay 
 
DNA synthesis was measured by tritiated thymidine uptake [3H-TdR] (Perkin Elmer, 
Boston, MA). MM cells (20,000cells/well) were incubated in 96-well culture plates 
(Costar, Cambridge, MA) in the presence of media or varying concentrations of 
A1014907, for 72 hours at 37°C. Cells were pulsed with 3H-TdR (0.5 μCi (0.185 
MBq)/well) during the last 4 hours of 72 hours time period and subsequently, harvested 
onto glass filters with an automatic cell harvester (Cambridge Technology, Cambridge, 
MA). These harvested cells were then counted counted using the LKB Betaplate 
scintillation counter (Wallac, Gaithersburg, MD). Each experiment was performed in 
triplicate and all experiments repeated three times. 
 
 
3.1.3.5 Bone marrow stromal cells co-culture experiments 
 
Bone marrow aspirates were subjected to Ficoll Paque gradient centrifugation 
(Amersham Pharmacia Biotech, Piscataway, NJ), and mononuclear cells (MNCs) were 
separated. MNCs were placed in 25-mm2 culture flasks in RPMI 1640 media (Sigma 
Chemical) containing 20% foetal bovine serum, 2 mM L-glutamine (Gibco), 100 U/mL 
penicillin, and 100μg/mL streptomycin (Gibco). Once confluent, the cells were 
trypsinized and passaged as needed.  
 
For the experiments, BMSCs were incubated in 96-well culture plates (approximately  
2000 to 5000 BMSCs/well) in 100 mls of supplemented RPMI-1460 as described. After 
18 hour incubation 20,000 MM cells were added to the wells and incubated with media 
alone or with different concentrations of A1014907 for 72 hours at 37°C. Cells were 
pulsed with 3H-TdR (0.5 μCi (0.185 MBq)/well) during the last 4 hours of 72 hours time 
period and subsequently, harvested onto glass filters with an automatic cell harvester 
(Cambridge Technology, Cambridge, MA). These harvested cells were then counted 
using the LKB Betaplate scintillation counter (Wallac, Gaithersburg, MD). Each 






3.1.3.6 Morphological analysis  
 
Cells were fixed on glass slides using methanol. Slides were dried and deparaffinized 
followed by staining with Haematoxylin dye. Stained slides were rinsed, dehydrated 
using ethanol and xylene and finally mounted with resinous mounting medium. 
Microscopic images were taken at 40× magnification highlighting morphological 
changes post A1014907 treatment. 
 
 
3.1.3.7 Cell cycle analysis  
 
Cells were treated with indicated doses of A1014907 for 24, 48 or 72 hrs. Cells were 
harvested, counted and washed with PBS following which 2 ml of cold 85% ethanol 
was added to the pellet while the tubes were vortexed. The tubes were left at 4° C 
overnight. Subsequently, the cells were pelleted and washed twice with PBS. The 
pellet was then resuspended in 0.1 ml of 5 μg/ml RNase (Sigma-Aldrich, St. Louis, 
MO) and incubated at 37° C for 30 minutes. PBS (0.9 ml) and 10 μl of 1 mg/ml 
propidium iodide (PI) (Sigma-Aldrich) were added and samples were held at 4° C till 
they were run on a Canto flow cytometer (BD Biosciences, San Jose, CA) and 
analysed using FlowJo software (Tree Star, Ashland, OR). 
 
 
3.1.3.8 Apoptosis assay  
 
Apoptosis induction by A1014907 in MM cell lines and patient cells was measured by 
annexin V/PI staining and flow cytometry [38–40]. Briefly, cells were washed twice in 
Annexin Binding Buffer (ABB) (10 mM HEPES pH 7.4, 140 mM NaCl, 2.5 mM CaCl2). 
100 μl cells (107 cells/ml) were stained with 3 μl of annexin V-FITC (Caltag, 
Burlingame, CA) for 15 minutes at room temperature. Cells were again washed with 
ABB and resuspended in 500 μl ABB containing 5 μl of 1 mg/ml PI (Sigma-Aldrich) and 






3.1.3.9 Western blotting  
 
Cells were lysed in RIPA buffer (50 mM HEPES (pH 7.4), 150 mM NaCl, 1% Triton X-
100, 30 mM sodium pyrophosphate, 5 mM EDTA) containing Halt Phosphatase 
Cocktail (Thermo Fisher Scientific, Rockford, IL), 1 mM phenylmethylsulphonyl-fluoride 
(PMSF) (Thermo Fischer) and protease inhibitor cocktail (PIC) (Sigma Aldrich). Protein 
lysate concentrations were measured using BCA assay (Thermo Fisher). Equal 
amounts of protein were loaded on Tris-Glycine gels and transferred onto nitrocellulose 
membranes (Bio-Rad, Hercules, CA). All antibodies were purchased from Cell 
Signalling Technology (Danvers, MA). Antigen-antibody complexes were detected 
using enhanced chemiluminescence (GE Healthcare, Piscataway, NJ).  
 
 
3.1.3.10 Receptor tyrosine kinase (RTK) array  
 
Human phosphor-RTK array was obtained from R&D Systems Inc, which allowed 
simultaneous screening of 49 different phosphorylated RTK’s. The array was 
processed following the manufacturer’s instructions. Briefly, protein extracts obtained 
from untreated or drug treated cells were added onto antibody coated nitrocellulose 
membrane After overnight incubation at 4° C, the membrane was washed to remove 
excess antibodies and incubated with anti phospho tyrosine HRP Detection antibody 


















3.1.4.1 Cell lines with t(4;14) translocation show increased sensitivity to 
A1014907(Fig 8) 
 
We first assessed the cytotoxic effects of A1014907 on MM cells. For this, we treated 
a panel of MM cell lines with various doses of A1014907 for 72 hrs and examined the 
cytotoxicity induced by the drug. We observed that cell lines OPM2, KMS11, KMS18, 
KMS28BM, H929, KAS6, LP1, OPM1 and KMS34 were significantly more sensitive to 
A1014907 treatment when compared to the other cell lines examined including MM1S, 


























     Fig8a: t(4;14) cell line viability after 72 hours treatment with indicated A101      
     concentrations       
 
                                                                                 











 3.1.4.2 t(4;14) translocation cells show increased anti-proliferative effect  to 
A1014907(fig 9a and b) 
 
We next assessed the antiproliferative effects of A1014907 on MM cells. For this, we 
treated the same panel of MM cell lines with various doses of A1014907 for 72 and 
examined the effects induced by the drug. We observed that cell lines OPM2, KMS11, 
KMS18, KMS28BM, H929, KAS6, LP1, OPM1 and KMS34 were significantly more 
sensitive to A1014907 treatment when compared to the other cell lines examined 




























Fig9a:  Anti-proliferative effects of A101 on t(4;14) cell lines  after 72 hours 
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3.1.4.3 t(4;14) translocation cells show increased cytotoxicity and anti-
proliferative effect  to A1014907(fig 10. a and b) 
 
We next jointly compared the cytotoxic(Fig 10.a) and anti-proliferative (Fig 10.b) effects 
of A1014907 on t(4;14) cell lines compared to non t(4;14) cells lines. The comparison 
of IC50 concentrations between the two sub group of cell lines showed a statistical 
significance using student t-test as shown below. 
 
 
Fig10a: Significant sensitivity of t(4;14) vs non-t(4;14) cell lines to A101 
 
 




3.1.4.4 A1014907 is effective in the presence of tumour promoting bone marrow 
stromal cells (Fig 11 – A,B and C) 
 
Bone marrow stromal cells (BMSCs) are important cellular components of the tumour 
microenvironment, whose interaction with MM cells contribute to disease progression 
and resistance to existing therapies[342]. We therefore examined if A1014907 was 
able to overcome the protective effects of BMSCs. We observed that A1014907 was 
able to inhibit proliferation of MM cells even in the presence of BMSCs in both t(4;14) 
























Fig11:  Increased antiproliferative effect of A101 on KMS11(A) and KMS18(B) 
compared to U266(C)  
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3.1.4.5 A1014907 induces polyploidy in all MM cell   
 
We next assessed if A1014907 induced cell division aberrations in both t(4;14) as 
well as non t(4;14) cells. For this experiment, we used KMS11, a t(4;14) and MM1S, 
a non t(4;14) cell line. G2M arrest and polyploidy was observed in both t(4;14)(Fig  
12a) and non t(4;14)(Fig. 13a) cell lines. This was evident as early as 24 hours with 
10 nM A1014907 treatment(Fig. 12 and 13).  
 
Morphological analysis showed that untreated control cells appeared to be of uniform 
cell and nuclear size. However, A1014907 caused the cells to increase in size with 
varied nuclear numbers/sizes within each cell indicative of cell division abnormality 



























Fig12a: A101 causes polyploidy at low dose(50nM) in KMS 11  


































KMS 11 72 hours Control KMS 11 24 hours 50nM A101 
KMS 11 48 hours 50nM A101 KMS 11 72 hours 50nM A101 
Fig12b: A101 causes polyploidy at low dose(50nM) in KMS 11 (H& E staining)  
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cell size  
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MM1.S 48 hours 50nM A101 MM1.S 72 hours 50nM A101 
MM1.S 72 hours Control MM1.S 24 hours 50nM A101 
Fig. 13b: A101 causes polyploidy at low dose(50nM) in MMS 1S – (H&E staining)   
Increasing 
cell size  
Increased cell 
size with less 
apoptotic cells  
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3.1.4.6  Polyploidy is a specific A1014907 mechanism of action (Fig 14) 
 
To confirm that the appearance of the 8N peak was due to the ability of A1014907 to 
induce polyploidy and not because of the drug’s ability to cause G2/M arrest, we 
treated MM1S cells with TG101209, a Jak2 inhibitor that we had shown in an earlier 
study to induce G2/M arrest. Results showed that TG101209 induced G2/M arrest 
without causing polyploidy further confirming that A1014907 does indeed induce 
























Fig14:  MM1S does not display polyploidy(A, B magnified scale); On treatment with 







3.1.4.7 A101 induces dose and time dependent apoptosis in t(4;14) cell lines 
(Annexin/Pi staining) (Fig 15 -16) 
 
Given that A1014907 induced more potent cell death in cells with t(4;14) 
translocation than in cells lacking this translocation, we next performed assays to 
confirm if the cell death occurred through induction of apoptosis. For this, we treated 
KMS11(Fig 15a and b) and MM1S(Fig 16a and b) cells with indicated concentrations 
of A1014907 for various time points. We observed that A1014907 induced potent 
apoptotic cell death in KMS11(Figure 15a and b).  
However, MM1S cells showed resistance to A1014907 treatment with minimal 
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3.1.4.8 A1014907 inhibits Aurora Kinases A and B and proteins involved in cell 
cycle machinery (Fig 17) 
 
We next examined the mechanism of action of A1014907. We treated two t(4;14) cell 
lines KMS11(data not shown) and KMS18 (Fig 17.a) and one non t(4;14)(Fig 17.b) 
cell line MM1S cells with indicated concentrations of A1014907 and examined the 
expression levels of aurora kinases and proteins involved in cell cycle progression.  
 
Down regulation of phospho Aurora A and phospho Histone H3, a substrate of Aurora 
B and a biomarker of mitosis in all the cell lines (Figure17.a and b ). Surprisingly, we 
also observed that A1014907 caused down regulation of total Aurora A in both cell 
lines. We speculate that A1014907 acts by blocking aurora A phosphorylation and in 
addition also by inducing the degradation of Aurora A.  
 
Our results from Figure  and clearly showed that A1014907 caused accumulation of 
cells in the G2M stage of the cell cycle in addition to polyploidy. We further examined 
the levels of proteins involved in cell cycle progression. A1014907 treatment reduced 
levels of Cdc2, cyclins A and B (Figure 17.a and b). Cdc2-Cyclin A complex regulates 
late S phase and early M phase while Cdc2-Cyclin B complex regulates M phase of 
the cell cycle. Thus, our data suggests that reduction in the level of Cdc2 and its 
binding partners cyclins A and B could be major factors contributing to the observed 
G2M arrest (Fig 12.a and 13.a). Cdc2-Cyclin B complex is a key regulator of nuclear 
envelope breakdown. Its inhibition could further contribute to a lack of or abnormal 
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Fig17:  A101 causes decrease in cell cycle specific Aurora kinase A and B in MM1S(fig 17a) and KMS18(fig 17b) along with 
reduction in cell cycle proteins 
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3.1.4.9 A1014907 inhibits FGFR3 in t(4;14) cells (fig 18)  
 
Our results so far suggest that A1014907 inhibits proliferation and causes polyploidy 
in all MM cell lines through the down regulation of Auroras A and B. However, 
A1014907 induced significant cell death only in MM cells with t(4;14) translocation  
which is associated with increased FGFR3 expression[343]. We therefore 
hypothesized that A1014907, in addition to being an aurora kinase inhibitor was also 
able to inhibit FGFR3 causing increased apoptosis in cells with t(4;14) translocation. 
We performed a receptor tyrosine kinase (RTK) array using KMS11 cells left 
untreated(fig 18.a) or treated(fig 18.b) with indicated dose of A1014907. The results 
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Fig18a: KMS 11 48hrs control 





3.1.4.10 A1014907 inhibits Stat3 in t(4;14) cell lines but not in non t(4;14) (fig 19) 
 
Activated FGFR3 can cause the up regulation of various signalling pathways 
including the PLCγ/PKC, Jak2/Stat3, PI3K/Akt, and Mek/Erk pathways [100]. To 
better understand which of these signalling pathways are involved in A1014907 
induced apoptosis, we performed western blotting using lysates from KMS11(data not 
shown), KMS18 and MM1S. KMS11(data not shown) and KMS18, which are both 
sensitive to A1014907 showed dose dependent downregulation of pStat3(fig 19.b). In 
MM1S, the cell line lacking FGFR3 expression, we did not observe down regulation 





























































             MM1S 
Fig19: A101 causes dose dependent decrease in pStat3 in KMS18(fig 19b) but not in MM1S(fig 19a)  
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3.1.4.11 A1014907 inhibits FGFR3 in t(4;14) cells promoting apoptosis but not in 
non t(4;14) cells (fig 20) 
 
We examined levels of the Bcl2 family of anti-apoptotic proteins and observed down 
regulation of Bcl-2 and Bcl-Xl in KMS11(data not shown). In addition, we observed 
activation of the intrinsic apoptotic pathway as shown by increased levels of cleaved 
caspases 9 and 3 (Fig 20.b) and inactivation of PARP (Figure 20.b) all indicating 
increase in cell death. It must be noted that such differences in apoptotic proteins 
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Fig 20 A101 induced apoptosis via intrinsic apoptotic in KMS18(fig 20b) but not in MM1S(fig 20a)  
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3.1.4.12 A1014907 activity is dependent on FGFR3 expression but not t(4;14) 
translocation(fig 21) 
 
To further confirm that A1014907 inhibits FGFR3, we checked the sensitivity of INA6, 
a non t(4;14) line that overexpresses FGFR3 to A1014907. We observed that INA6 
was sensitive to A1014907 like the t(4;14) cell lines (Figure 12.a). To further confirm 
that the activity of A1014907 is dependent on FGFR3 expression and not due to the 
presence of t(4;14) translocation, we examined the effect of A1014907 on two MM 
cell lines JIM2 and JIM3, both of which are t(4;14) cell lines but negative for FGFR3 
expression. A1014907 was unable to induce pronounced cell death in both these cell 
lines (data not shown).  
 
As further proof of specificity of target, we treated CLL B cells from two patients with 
indicated doses of A1014907. Clear induction of cell death in both these patients (fig 
21b). Both the patients were positive for FGFR3 expression as determined by flow 
cytometry (data not shown). Taken together, we show that A1014907 induces cell 
death in FGFR3 expressing MM cells. FGFR3 expression could therefore serve as a 
















































Fig21b: CLL patients expressing FGFR3  t(4;14) are sensitive to low dose(50nM) 
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Loss of functional p53, forms crucial component of prognostically unfavorable of high 
risk genetic aberrations seen in Multiple Myeloma (MM). This loss is usually 
monoallelic and is distributed heterogeneously amongst ethnically diverse population 
with no predilection for age and is associated with reduced treatment responses, 
shorter PFS and OS. The mutations of the tumor suppressor gene p53 are rare events 
(3%) in MM patients[50]. Its deletions (Del 17p13.1) are more frequent and have been 
reported in about 11 % [69, 344] of patients with newly diagnosed Multiple Myeloma 
and increase in frequency as the disease advances [125].   
 
P53(17p13.1) regulates major pathways of cellular homeostasis in stressed or 
damaged cells. Its functional loss exists in more than 50 % of human cancer [125, 133, 
135, 345-349] making it one of the most studied tumor regulator proteins. Functional 
loss of p53 in MM is associated with a dismal disease prognosis and has a higher 
association with uncommon MM presentations including extramedullary disease and 
plasma cell leukemia [69, 101, 138, 139, 344, 350-352]. Although some treatment 
response has been reported with Bortezomib based regimens[141, 353], patients with 
Del17p usually achieve unsatisfactory survival benefits to novel agent treatment and/or  
Stem cell transplantation (SCT), when compared to the MM patients without Del17p[67, 
69, 94, 97, 344, 354, 355].   
 
Given the aggressive disease course and poor survival outcomes, it is essential to 
premeditate optimal strategy for patients with del17p. Further, predictability of the 
patients at risk of developing del17p is essential as the therapeutic options are limited 
and newer alternatives need to be explored. Due to inherent lower frequency of the 
abnormality, it is challenging to sufficiently study natural history of patients with del17p. 
With our study we aim to identify and study the outcomes of this unique cohort of 







3.2.1 Aims of the study 
 
Identify and study the natural history, treatment responses and 
outcomes of patients with del17p either at diagnosis(de-novo) or 
acquired during the disease course in MM patients: 
 
 
Aim IIa : Study natural history of patients with de-novo del17p: 
 
• Identify and assess impact of factors affecting outcomes  
 
Aim IIb: Study natural history of patients with acquired del17p: 
 



























3.3 Aim IIa: Study natural history of patients with de-novo 
del17p  
 
3.3.1 Patients  
 
Patients identification :  
 
We reviewed the Dysproteinaemia database at Mayo Clinic, Rochester and electronic 
medical records, to identify patients with MM who underwent FISH testing between 
2004 and August 2016 and demonstrated del (17p) at diagnosis or within 6 months of 
the diagnosis of MM. De novo del(17p) was defined as del(17p13.1), which includes 
the p53 gene region, and/or monosomy for chromosome 17. Relative loss of 17p was 




We excluded all patients who had MM with an amyloid related systemic syndrome (n 
= 4) or PC leukaemia before the index FISH (n = 31), or for whom details about initial 




Three hundred and ten (310) patients satisfied the inclusion criteria. For each patient 
with del(17p), we identified two patients with MM matched for age and time period of 
diagnosis, who did not have del(17p) by FISH within 6 months from diagnosis and 
satisfied the other inclusion criteria. We subdivided the control group (n = 620) into a 
high-risk translocation (HRT) group [with t(4;14), t(14;16) or t(14;20)] (n = 79) and a 
standard- risk (SR) group (n=541) for comparing the outcomes.  
 
The Mayo Clinic Institutional Review Board approved the study. The study was 
conducted in accordance with the Declaration of Helsinki and the Health Insurance 




Patient data  
 
We collected data regarding demographic characteristics, pre-treatment laboratory 
parameters, treatment administered, best response to induction, progression, and 
survival status at final data cut-off by retrospective chart review. The data cut-off date 
was 31 January 2018. In all patients, diagnosis of MM was made based on the 
standard criteria, which were in use during the defined period42,43.  
 
 
Patient assessment criteria 
 
We used the international staging system (ISS) to risk stratify patients where serum 
beta-2-microglobulin and albumin levels were available before starting treat- ment4. 
High PC proliferative rate was defined by a PC labelling index of ≥1.5% or a monotypic 
PC- S-phase fraction of ≥3% in the flow cytometric PC proliferation study44. We 
assessed the best response to induction using the International Myeloma Working 
Group (IMWG) consensus response criteria45. Clinical benefit rate (CBR) was defined 
as the proportion of patients who obtained at least a minor response as the best 
response to induction. We defined ‘early SCT’ as SCT done within 12 months of 
starting treatment for MM.  
 
 
3.3.2 Outcome measures  
 
Our primary outcome was OS, defined as duration from diagnosis of MM to death due 
to any cause, patients being censored if they were alive at the last follow-up46. 
Secondary outcome measures included best response to induction therapy and PFS. 
We defined overall response rate (ORR) as the proportion of patients attaining a partial 
response (PR) or better following induction. We defined PFS as the duration from the 
initiation of treatment to first progression or death due to any cause and we censored 








3.3.3.1 FISH  
 
Bone marrow aspirate samples enriched for mono- nuclear cells by the Ficoll method 
were used for preparing cytospin slides. Cytoplasmic immunoglobulin staining was 
used to identify plasma cells and the FISH analysis was performed as described 
previously from our institu- tion using the following probes: 3cen (D3Z1), 7cen (D7Z1), 
9cen (D9Z1), 15cen (D15Z4), 11q13 (CCND1- XT), 13q14 (RB1), 13q34 (LAMP1), 
17p13.1 (p53), 17cen (D17Z1), 14q32 (IGH-XT), 14q32 (3′IGH,5′IGH), 4p16.3 
(FGFR3), 16q23 (c-MAF), 6p21 (CCND3), 20q12 (MAFB), 1p (p73), and (1q22)8. The 
cut-points for a positive test were 7 and 9% for deletion 17p13.1 and monosomy 17, 
respectively. Hyperdiploidy was defined as presence of trisomy/tetrasomy of ≥2 odd-
numbered chromosomes.  
 
 
3.3.3.2 Statistical analysis  
 
We summarized categorical variables as proportions and continuous variables as 
medians (range). We used Fisher’s exact test to compare categorical variables and 
the non- parametric Mann–Whitney U and Kruskall–Wallis tests as appropriate to 
compare continuous variables between groups. We estimated PFS and OS using the 
Kaplan–Meier method and used the log-rank test to compare them between groups. 
We used the Cox proportional hazards model to identify baseline factors affecting PFS 
and OS. A two-tailed p-value <0.05 was considered significant for all statistical tests. 
We used JMP® Pro 12.0 software package (SAS Institute Inc., Cary, NC, USA) for all 








3.3.4 Results  
 
3.3.4.1 Baseline characteristics( table 8) 
 
A comparison of the baseline demographic and laboratory characteristics across the 
patient groups is given in Table 1 and the other cytogenetic abnormalities detected are 
given in Table 2. A higher proportion of patients with del(17p) had a higher PC 
proliferative rate and elevated lactate dehydrogenase (LDH) at diagnosis. 
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Table 8. Demographic and laboratory characteristics of the study population at diagnosis (n=930) 









Age at diagnosis, median (range) 64.1 (33.8-90.9) 64.2 (35.2-91.0) 60.4 (37.1-81.2) 64.8 (35.2-91.0) 0.787; 0.060 
Age ≥65 years, n (%) 147 (47.4) 296 (47.7) 29 (36.7) 267 (49.3) 0.945; 0.108 
Female gender, n (%) 122 (39.3) 242 (39.0) 41 (51.9) 201 (37.1) 0.924; 0.044 
Haemoglobin, g/L, median (range), (n=907) 10.7(4.7-16.8) 11.2 (5.8-16) 10.6 (5.8-14.7) 11.2 (5.9-16.0) 0.015; 0.005 
Calcium, mg/dL, median (range), (n=849) 9.7 (7.7-16.8) 9.6 (7.1-17.1) 9.4 (7.7-16.6) 9.6 (7.1-17.1) 0.089; 0.268 
Creatinine >2 mg/dL, n(%), (n=883) 52 (18.4) 82 (13.8) 14 (18.7) 68 (12.9) 0.071; 0.121 
Bone disease at diagnosis, n (%) 243 (78.4) 474 (76.4) 48 (60.8) 426 (78.4) 0.562; 0.003 
Lytic lesions, n (%) 205 (66.1) 419 (67.6) 45 (57.0) 374 (69.1) 0.658; 0.092 
Pathological fractures, n (%) 50 (16.1) 104 (16.8) 6 (7.6) 98 (18.1) 0.852; 0.050 
Vertebral compression fractures, n (%) 108 (34.8) 403 (65.0) 18 (22.8) 199 (36.8) 1.0; 0.048 
Bone marrow plasma cell percentage, 
median (range), (n=920) 50 (2-100) 
50 (2-100) 50 (10-100) 46 (2-100) 0.033; 0.013 
High plasma cell proliferative rate†, n (%) 
(n=504) 42 (30.0) 
59 (16.1) 7 (16.3) 52 (16.1) <0.001; 0.003 
M-protein level, g/dL, median (range), 
(n=876) 2.3 (0-8.2) 
2.6 (0-10) 3.7 (0-9) 2.5 (0-10) 0.154; <0.001 
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M-protein isotype, n (%)      
IgG 176 (56.8) 367 (59.2) 46 (58.2) 321 (59.3)  
IgA 64 (20.7) 136 (22.0) 27 (34.2) 109 (20.1) 0.605; 0.031 
Light chain only 60 (19.3) 100 (16.1) 5 (6.3) 95 (17.6)  
Others 10 (3.2) 17 (2.7) 1 (1.3) 16 (3.0)  
Difference between involved and uninvolved 
free light chain , mg/dL, median (range), 
(n=780) 
61.3 (0-2589.0) 46.2 (0-6620) 40.53 (0.4-1999.7) 46.9 (0-6620) 0.126; 0.212 
Risk stratification, n (%)      
ISS I/II (n=541) 154 (62.3) 387 (69.2) 44 (63.8) 343 (70.0) 0.061; 0.092 
ISS III (n=265) 93 (36.7) 172 (30.8) 25 (36.2) 147 (30.0)  
Elevated LDH, (n=671) 49 (23.8) 66 (14.2) 7 (13.0) 59 (14.4) 0.004; 0.012 
*p-value for Fischer’s exact test or the non-parametric Mann-Whitney U or Kruskall Wallis tests as appropriate. The first value represents comparison 
between the de novo del(17p) and all controls and the second value represents comparison across de novo del(17p), high-risk translocation and standard-
risk groups. †High plasma cell proliferative rate was defined by a plasma cell labelling index of ≥1.5% or a monotypic plasma cell S-phase fraction of ≥3%. 





3.3.4.2 Baseline cytogenetics( table 9) 
 
HRTs were more likely to coexist in the del(17p) group (24.2%) when compared to the 
control group (12.7%) (P < 0.001). Among patients for whom testing for del(1p) and 
del(1q) were available, they were detected at a similar frequency in the del(17p) (31.9%) 
and the control group (31.1%) (P = 0.908). Overall, any high-risk abnormality other 
than del(17p) occurred in 31.6% patients with del (17p) and 17.7% patients in the 
control group (P < 0.001). Out of 310 patients in the del(17p) group, 246 (79.4%) 
patients had del(17p13.1) and 41 (13.2%) patients had monosomy 17. Two patients 
(0.6%) had concurrent del (17p13.1) and monosomy 17. Relative loss of 17p was 





















Table 9. Cytogenetic profiles of patients based on interphase fluorescent in-situ hybridization (n=930) 
Cytogenetic abnormality De novo del(17p) 
(n=310) 







t(4;14) 48 (15.5) 49 (7.9) 49 (62.0) - <0.001 
t(6;14)† 4 (1.7) 7 (1.5) - 7 (1.7) 1.000 
t(11;14) 45 (14.5) 131 (21.1) - 131 (24.2) 0.016 
t(14;16) 24 (7.7) 22 (3.2) 22 (27.8) - 0.009 
t(14;20)† 3 (1.2) 9 (1.9) 9 (13.8) - 0.760 
Unspecified immunoglobulin heavy chain (IgH) 
rearrangement/ IgH variable region deletion 
19 (6.1) 56 (9.0) - 56 (10.3) 0.159 
Hyperdiploidy (trisomy or tetrasomy) 154 (49.7) 345 (55.6) 31 (39.2) 314 (58.0) 0.002; 0.094 
Del (13q) and/or monosomy 13 200 (64.5) 257 (41.4) 64 (81.0) 193 (35.7) <0.001; <0.001 
Del (13q) 39 (12.6) 51 (8.2) 11 (13.9) 40 (7.4) 0.045; 0.017 
Monosomy 13 163 (52.6) 213 (34.3) 57 (72.5) 156 (28.8) <0.001; <0.001 
1q gain‡ 21 (29.2) 38 (31.1) 11 (68.7) 27 (25.5) 0.872; 0.003 
Del (1p) ‡ 4 (5.6) 1 (0.8) 1 (6.2) 0 (0) 0.064; 0.021 
*p-value for Fischer’s exact test. Comparison between del(17p) and all controls when only one value is present and the second value when present 
represents comparison across del(17p), high-risk translocation and standard-risk groups.  †Calculation is limited to patients who had iFISH after May 2009 
(n=716) when probes for these abnormalities were introduced. ‡Calculation limited to patients who had iFISH after August 2014 (n=194) when probe for 1q 





3.3.4.3 Patient Follow-up  
 
The median follow-up for all the patients was 63.5 months (95% CI, 58.3–67.5); 54.5 
(95% CI, 49.8–66.9), and 65.7 (95% CI, 59.2–71.3) months for the del(17p) and control 
groups, respectively. At data cut-off, 169 (54.5%), 32 (40.5%) and 174 (32.2%) patients, 
respectively in del(17p), HRT and SR groups had died.  
 
 
3.3.4.4 Induction therapy (Fig 22a)  
 
The major classes of induction therapy received by patients in the del(17p), HRT, and 
SR groups are shown in Fig. 1a. Patients with del(17p) and HRT were more likely to 
receive a PI-containing regimen (71.1 and 73.4%, respectively) when compared to SR 
patients (51.8%) (P < 0.001). Best response to induction was evaluable in 289 (93.2%), 
79 (100%) and 534 (98.7%) patients, respectively, in the three groups.  
 
 
3.3.4.5 Response to induction (Fig 22b) 
 
The best responses obtained during induction in these patients are shown in Fig. 1b. 
ORR was lower in patients with del(17p) (76.5%) compared to those patients with HRT 
(87.3%) or SR disease (84.8%) (P= 0.006). Among patients who received PI + IMiD- 
based induction, the ORRs were 85.4, 94.7, and 97.1% in the three groups (P = 0.009), 
while VGPR or better rates in the three groups were 52.7, 78.9, and 63.7%, 
respectively (P = 0.054). Similarly, in patients who received a PI-containing regimen, 
the ORRs were 78.7, 93.1, and 84.4%, respectively, in the three groups (P = 0.026) 












3.3.4.6 Survival outcomes(Fig 23)  
 
The estimated median PFS for del(17p), HRT and SR groups were 21.1 months (95% 
CI, 17.8–23.9), 22.0 months (95% CI, 16.7–26.8) and 30.1 months (95% CI, 27.5–31.5) 
respectively (P = 0.437 for del(17p) vs. HRT and P < 0.001 for del(17p) vs. SR) (Fig. 
23a). The estimated median OS for the three groups were 47.3 months (95% CI, 42.7–
55.9), 79.1 months (95% CI, 60.5-not reached[NR]), and 109.8 months (95% CI, 99.9–
125.6), respectively, (P = 0.007 for del(17p) vs. HRT and P < 0.001 for del(17p) vs. SR) 
(Fig. 23b). The median PFS for patients with relative loss of 17p was 22.1 months (95% 
CI, 8.7–51.8) and was comparable to 21.2 months (95% CI, 17.8–25.0) seen in patients 
with del17p or monosomy 17 (P = 0.485). Similarly, the median OS for the two groups 
were comparable: 48.7 months (95% CI, 32.1-NR) vs. 47.3 months (95% CI, 41.6–






Fig 23: a) PFS; b) OS of patients with del17p compared to other high risk translocations and standard risk patients  
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3.3.4.7 Impact of FISH abnormalities(Fig 24) 
 
To elucidate the impact of combinations of FISH abnormalities, we divided the entire 
patient cohort (cases and controls) into the following groups: cases were divided into 
del(17p) alone (n = 135), del(17p) with hyper- diploidy (n = 100), del(17p) with HRT 
(irrespective of presence of hyperdiploidy) (n = 75), and controls were divided into HRT 
(irrespective of presence of hyperdiploidy) (n = 79) and SR patients (n = 541). The 
median PFS in the above five groups were 22.4 months (95% CI, 17.8–27.0), 27.3 
months (95% CI, 19.6–34.5), 14.7 months (95% CI, 9.8–17.9), 22.0 months (95% CI, 
16.7–26.8), and 30.1 months (95% CI, 27.5–31.5), respectively, (P < 0.001)(Fig 24a). 
The median OS in the above five groups were 51.4 months (95% CI, 42.1–62.8), 60.3 
months (95% CI, 47.8–89.6), 29.5 months (95% CI, 20.0–38.1), 79.1 months (95% CI, 
60.5-not reached), and 109.8 months (95% CI, 99.9–125.6), respectively, (P < 0.001) 
(Fig. 24b). Presence of hyperdiploidy was associated with longer PFS (P = 0.007) and 
only a trend toward longer OS (P = 0.272) in del(17p) patients. Coexistent HRT 










3.3.4.8 Sub-group analysis for survival outcomes(table 10)  
  
We stratified patients according to age (using 65 years as cut-off), ISS stage, LDH, 
and PC proliferative rate at diagnosis and the type of induction therapy. The results  
are shown in Table . There was no difference in PFS between patients with del(17p) 
and HRT across all the subgroups analyzed. The OS was shorter in del(17p) group 
compared to the HRT group in patients with age <65 years, ISS I/II stage and those 
patients who received PI-containing induction regimen or early SCT. However, the 
difference was abolished and both groups had similar OS in presence of adverse 
factors, such as advanced age, ISS III stage or when they received non-PI containing 
induction regimens or delayed or no SCT. This loss of difference in OS was primarily 
due to a marked reduction in OS in the HRT group in presence of additional risk factors 
as shown in Table 10. For example, in the del(17p) group, ISS I/II and ISS III stages 
were associated with median OS of 58.3 and 33.3 months, respectively, while in the 
HRT group, the OS decreased from 81.6 months in ISS I/II stages to 38.7 months in 
ISS III stage. Similarly, a non-PI-containing induction was associated with reduction of 
median OS from 54.3 months in the del(17p) group to 45.2 months, while it decreased 
from not reached to 67.1 months in the HRT group. Across all subgroups, the SR group 






Table 10. Sub-group analysis for survival outcomes in patients based on prognostic factors and therapy 
Survival outcomes and subgroups De novo del(17p) High-risk 
translocation 
Standard-risk P* 
Progression free survival     
Age <65 (n=487) 21.0 (16.8-27.0) 25.4 (17.5-32.6) 32.3 (28.7-37.7) 0.176; <0.001 
Age ≥65 (n=443) 21.3 (16.0-25.8) 16.6 (11.2-25.5) 27.4 (25.3-30.6) 0.520; 0.002 
     
ISS I/II (n=541) 27.0 (21.1-30.3) 24.6 (17.1-31.5) 30.9 (29.1-34.8) 0.699; 0.002 
ISS III (n=265) 14.3 (9.6-16.9) 16.7 (5.1-34.4) 24.8 (19.7-28.5) 0.212; <0.001 
     
PI-containing induction (n=557) 22.6 (18.4-27.5) 25.0 (18.1-32.6) 29.5 (26.3-31.8) 0.336; <0.001 
Others (n=371) 16.1 (13.8-22.0) 13.3 (5.1-25.5) 30.6 (27.1-33.8) 0.840; <0.001 
     
Normal LDH (n=556) 22.5 (18.4-28.2) 18.4 (15.1-25.4) 30.8 (28.0-33.1) 0.241; <0.001 
High LDH (n=115) 16.1 (8.3-17.9) 6.7 (1.5-21.9) 27.1 (18.3-32.3) 0.245; <0.001 
     
High PC proliferative rate (n= 101) 10.4 (5.1-18.6) 6.7 (2.3-17.1) 25.0 (17.9-31.3) 0.264; <0.001 
Low PC proliferative rate (n=405) 22.3 (17.8-28.8) 16.6 (13.3-22.0) 29.8 (26.3-32.1) 0.106; 0.044 
     
Overall survival     
Age <65 (n=487) 55.2 (42.0-67.4) 81.6 (60.5-NR) 130.6 (112.6-NR) 0.030; <0.001 
Age ≥65 (n=443) 44.7 (37.5-54.6) 67.1 (25.2-NR) 78.6 (70.4-103.6) 0.201; <0.001 
     
ISS I/II (n=541) 58.3 (45.3-71.8) 81.6 (60.5-NR) 112.3 (103.6-NR) 0.039; <0.001 
ISS III (n=265) 33.3 (23.2-44.7) 38.7 (21.1-NR) 64.7 (59.6-124.4) 0.179; <0.001 
     
Normal LDH (n=556) 53.9 (43.9-65.9) 67.1 (38.7-81.6) 105.0 (83.9-125.6) 0.322; <0.001 
High LDH (n=115) 26.8 (18.6-46.4) NR (7.3-NR) 106.1 (71.7-NR) 0.295; <0.001 
     
High PC proliferative rate (n= 101) 32.9 (15.2-54.9) 21.5 (7.6-28.0) 62.5 (42.7-85.9) 0.217; 0.008 
Low PC proliferative rate (n=405) 47.8 (41.6-67.4) 72.3 (38.7-NR) 103.6 (80.4-130.6) 0.144; <0.001 
     
PI-containing induction (n=557) 54.3 (40.7-62.6) NR (54.0-NR) 124.4 (79.9-NR) 0.007; <0.001 
Others (n=371) 45.2 (36.5-58.3) 67.1 (27.5-85.4) 106.1 (84.8-125.6) 0.405; <0.001 
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Early SCT (n=462) 54.9 (45.3-66.5) 85.4 (72.3-NR) 130.6 (106.1-NR) 0.038; <0.001 
Delayed or no SCT (n=468) 37.5 (25.7-45.4) 60.5 (27.5-NR) 83.9 (74.0-112.2) 0.098; <0.001 
*P-value for log-rank test in Kaplan Meier analysis. The first value represents comparison between del(17p) and high-risk 
translocation groups and the second value represents comparison between del(17p) and standard-risk groups. ISS-International 






3.3.4.9 Predictors of outcome in patients with de novo del(17p)(Table 11)  
 
We performed univariable analysis with age ≥65 vs. <65 years, serum creatinine >2 vs. 
≤2 mg/dL, bone marrow PC percentage ≥50 vs. <50%, ISS III vs. I/II stage, elevated 
vs. normal LDH, presence vs. absence of an HRT, presence vs. absence of monosomy 
13, presence vs. absence of hyperdiploidy, high vs. low PC proliferation rate and PI- 
containing vs. other induction therapy as independent variables to determine their 
association with PFS and OS. Variables with a p-value <0.1 in univariable analysis 
were included as potential predictors in multivariable Cox proportional hazards model 
and we arrived at a final model using stepwise backward elimination. To assess the 
impact of percentage of PCs with del(17p), we included each cut-point (viz. 20, 30, 40, 
50, and 60%) with the above predictors. The results of the analysis are shown in Table 
11. ISS stage III disease, elevated LDH and coexistent HRTs were associated with 
reduced OS, while percentage of PCs with del(17p) was not a significant predictor in 




Table 11. Effect of baseline characteristics on survival measures in patients with de novo del(17p) (n=310) 
 Progression-free survival (PFS) Overall survival (OS) 
Independent variable p-value for 
univariable 
analysis 














Age ≥65 vs <65 years 
(147 vs. 163) 0.714 NI - 0.010 1.40 (0.96-2.04) 0.079 
Serum creatinine >2 vs ≤2 
mg/dL (52 vs. 231) 0.027 1.18 (0.66-2.00) 0.561 0.072 0.84 (0.48-1.43) 0.534 
Bone marrow PCs ≥50% (164 
vs. 140) 0.110 NI - 0.536 NI - 
ISS III vs I/II stage (93 vs. 
154) <0.001 1.92 (1.34-2.73) <0.001 <0.001 2.08 (1.42-3.04) <0.001 
Elevated vs normal LDH (49 
vs. 157) 0.001 1.71 (1.04-2.53) 0.011 0.003 1.83 (1.16-2.80) 0.009 
High-risk translocation vs. no 
high-risk translocation (75 vs. 
235) 
0.001 1.44 (0.97-2.10) 0.071 <0.001 1.53 (1.01-2.27) 0.044 
Monosomy 13 vs no 
monosomy 13 (163 vs. 147) 0.020 1.08 (0.75-1.57) 0.672 0.024 1.04 (0.63-1.74) 0.883 
HRD vs. no HRD (154 vs. 
156) <0.001 0.72 (0.51-1.03) 0.070 0.010 0.75 (0.51-1.11) 0.155 
High PC proliferative rate vs. 
low proliferative rate (42 vs. 
98) 
<0.001 1.56 (0.93-2.60) 0.090 0.042  0.87 (0.48-1.54) 0.630 
PI-containing induction vs 
other induction therapy (219 
vs. 89) 






Percentage of plasma cells 
with del(17p)       
• ≥20% vs. <20% (224 vs. 
36) 0.074 0.99 (0.35-4.16) 0.990 <0.001 1.15 (0.41-4.85) 0.812 
• ≥30%  vs. <30% (207 vs. 
53) 0.057 1.93 (1.14-3.53) 0.013 <0.001 1.44 (0.80-2.86) 0.241 
• ≥40%  vs. <40% (193 vs. 
67) 0.012 2.04 (1.28-3.44) 0.002 0.001 1.29 (0.66-2.77) 0.473 
• ≥50% vs. <50% (170 vs. 
90) 0.025 1.60 (1.06-2.50) 0.023 0.011 1.23 (0.68-2.32) 0.495 
• ≥60%  vs. <60% (153 vs. 
107) 0.050 1.10 (0.65-1.89) 0.724 <0.001 1.36 (0.89-2.13) 0.1531 
HR-Hazard ratio, HRD- Hyperdiploidy, LDH-Lactate dehydrogenase, NI- Not included in analysis, PC- plasma cell, and PI- proteasome 
inhibitor. The final multivariable model included 174 patients for PFS and 191 patients for OS for whom the parameters were available. 
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3.4 Aim IIb: Natural History of 17p in MM : Acquired del17p 
 
 
3.4.1 Patients  
 
Patient identification and timing of FISH evaluation  
 
We reviewed the Dysproteinaemia database at Mayo Clinic, MN to identify 80 patients 
with MM and acquired del(17p), defined as first FISH test negative for del(17p) with 
detection of del(17p) on a follow-up FISH test. 76 patients were included in the analysis. 
All patients had FISH testing between 2004 and August 2016. Fifty seven (75%) 
patients had their first FISH within 6 months of diagnosis of MM; 19 (25%) patients had 





Of these, 76 patients had RRMM, while in 2 patients, del(17p) was detected prior to 
stem cell transplant (SCT) after having attained a response to previous line of therapy. 
In two patients, del(17p) was detected during assessment for stem cell harvest after a 
partial response (PR) was attained after induction therapy. These 4 patients were 
excluded from evaluation.   
  
 
Control selection and FISH timing 
 
Del(17p) included interstitial deletion involving the short arm of chromosome 17 
[del(17p13.1)] and/or monosomy 17. We identified 2 control patients for each case, 
who were diagnosed during the same time period, but did not demonstrate del(17p) at 
any time during follow-up. The cases and controls were not matched for potential 
predictors of acquisition of del(17p) including age, cytogenetic abnormalities or initial 
treatment. Control patients (n=152) had at least two FISH tests negative for del(17p), 
the second test being at a comparable time point or later relative to timing of detection 
of del(17p) in the respective case. The second FISH test was done at relapse. We also 
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compared survival outcomes in the acquired del(17p) group with a cohort of 310 
patients with del(17p) detected at diagnosis. 
 
 
3.4.2 Response criteria 
 
We defined responses to treatment using the 2016 Revised International Myeloma 
Working Group Criteria[356]. Progression free survival (PFS) was defined as the 
duration between initiation of therapy and progression or death, and OS was defined 
as the duration from diagnosis of MM or detection of del(17p) to death due to any 
cause.[357] Number of lines of therapy were defined according to accepted 




3.4.3 Methods  
 
3.4.3.1 FISH probes and testing  
 
Bone marrow aspirate samples enriched for mononuclear cells by the Ficoll method 
were used for preparing cytospin slides. Cytoplasmic immunoglobulin staining was 
used to identify PCs and the FISH analysis was performed as described previously 
from our institution using the following probes: 3cen (D3Z1), 7cen (D7Z1), 9cen (D9Z1), 
15cen (D15Z4), 11q13 (CCND1-XT), 13q14 (RB1), 13q34 (LAMP1), 17p13.1 (p53), 
17cen (D17Z1), 14q32 (IGH-XT), 14q32 (3′IGH,5′IGH), 4p16.3 (FGFR3), 16q23 (c-
MAF), 6p21 (CCND3), 20q12 (MAFB), 1p32 (p73), and (1q22).[101]  The cut-points for 
a positive test were 7% and 9% for del(17p13.1) and monosomy 17 respectively. 
Relative loss of del(17p) was defined as del(17p) with trisomy/tetrasomy involving 
chromosome 17. High-risk translocations (HRTs) included t(4;14), t(14;16) and t(14;20). 
Hyperdiploidy was defined as presence of trisomy and/or tetrasomy of 2 or more odd-






3.4.3.2 Estimation of plasma cell proliferative rate 
 
PC proliferative rate was defined as the proportion of clonal PCs actively proliferating 
in the S-phase of cell cycle.  Slide technique using the deoxyuridine method (called PC 
labeling index-PCLI) was used for this till May 2012.[359] After that, PCLI was 
supplanted by flow cytometric technique. Briefly, this involves identification of 
immunophenotypically atypical PCs and estimating the DNA content in PCs. By 
appropriate gating, proportion of atypical PCs in the S-phase is estimated. The details 
of the technique are summarized in a recent publication.[360] High PC proliferative 
rate was defined by a PCLI of ≥1.5% or a PC- S-phase fraction of ≥3% in the flow 
cytometric technique.[361, 362] 
 
 
3.4.3.3 Statistical analysis 
 
Categorical variables were summarized as proportions and compared between groups 
using Fisher’s exact test. Continuous variables were summarized as median and 
compared between groups using non-parametric Mann-Whitney U test. We estimated 
PFS and OS using the Kaplan-Meier method and used the log-rank test to compare 
them between groups. We used Cox proportional hazards model to identify factors at 
detection of del(17p) affecting PFS and OS. Odds ratio (OR) was calculated to identify 
factors at diagnosis of MM associated with later detection of del(17p) by FISH. A two-
tailed P <0.05 was considered significant for all statistical tests. We used JMP® Pro 











3.4.4 Results  
 
3.4.4.1 Baseline characteristics(table 12) 
 
The characteristics of 76 patients with acquired del(17p) at initial diagnosis of MM, 152 
control patients at diagnosis and the acquired del(17p) cohort at detection of del(17p) 
are shown in Table 12. Patients with acquired del(17p) and controls were similar with 
respect to baseline characteristics, and initial treatment, except relatively low 
hemoglobin at diagnosis in cases (median- 10.8 g/dL vs. 11.3 g/dL; P=0.035), higher 
occurrence of t(4;14) among cases (15.8% vs. 6.6%; P=0.033) and higher proportion 
of patients with elevated lactate dehydrogenase (LDH) among evaluable cases [13.7% 
(7/51) vs. 4.1% (5/121); P=0.043] relative to controls. The characteristics of de novo 
del(17p) group have been published elsewhere[363]. Briefly, 47.4% patients were 65 
years or older; 36.7% patients had international staging system (ISS) III stage and 23.8% 
patients had elevated LDH; and 24.4% patients had concurrent HRTs. More than 95% 
patients in this cohort were treated initially with novel agents (PI+IMiD- 38.6%; PI- 
32.5%; and IMiD- 25.6). 56% patients received SCT during their treatment.
144 
 
Table 12. Characteristics of patients with acquired del(17p) at diagnosis, and detection of del(17p) (n=76) and control patients at diagnosis (n=152) 





at detection of 
del(17p) (n=76) 
P* (Acquired del(17p) 
vs. control at diagnosis) 
Age, years, median (range) 61.9 (42.4-80.9) 61.4 (28.8-84.7) 65.6 (44.6-82.2) 0.972 
Age ≥65 years, n (%) 28 (36.8) 51 (33.5) 39 (51.3) 0.659 
Female gender, n (%) 30 (39.5) 63 (41.4) 30 (39.5) 0.886 
Haemoglobin, g/L, median (range), (n=69/150/75) 10.8 (5.4-14.5) 11.3 (7.1-16.7) 10.4 (7.2-14.7) 0.035 
Calcium, mg/dL, median (range), (n=60/146/73) 9.6 (7.2-15.4) 9.6 (7.9-15) 9.5 (7.1-11.5) 0.598 
Creatinine >2 mg/dL, n(%), (n=64/145/74) 8 (12.5) 10 (6.9) 4 (5.4) 0.191 
BMPC percentage, median (range), (n=70/150/75) 40 (4-93) 50 (3-98) 40 (2-100) 0.384 
High plasma cell proliferative rate*, n (%) (n=45/106/65) 14 (31.1) 22 (20.7) 32 (49.2) 0.211 
Percentage of plasma cells with del(17p), median (range) (n=-/-71) - - 89 (9-100)  
M-protein level, g/dL, median (range), (n=65/146/74) 2.8 (0-12.3) 2.7 (0-6.8) 1.8 (0-6.4) 0.999 
M-protein isotype, n (%), (n=76/152/76)     
IgG 46 (60.5) 88 (57.9) 46 (60.5) 0.097 
IgA 21 (27.6) 36 (23.7) 21 (27.6)  
Light chain 5 (6.6) 25 (16.4) 5 (6.6)  
Others 4 (5.3) 3 (2.0) 4 (5.3)  
ISS I/II vs. III, n (%), (n=56/136/56) 42 (75.0)/ 14 (25.0) 110 (80.9)/ 26 (19.1) 
43 (76.8)/ 13 
(23.2) 
0.434 
Elevated LDH, n (%), (n=51/121/61) 7 (13.7) 5 (4.1) 21 (33.4) 0.043 
Prior lines of therapy, median (range)   2 (1-10)  




Immunomodulatory drug exposed/ refractory, n (%)   70 (92.1)/57 (75.0) 
 
Alkylating agent exposed/ refractory, n (%)   60 (78.9)/25 (32.9) 
 
Proteasome inhibitor and immunomodulatory drug refractory   30 (39.5)  
     
*P for Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables. †Calculation is limited to cases and controls who had FISH after May 2009 [n=37 and 
n=69 for cases and controls at diagnosis and n=68 for cases at detection of del(17p)] when probes for these abnormalities were introduced. ‡Calculation limited to cases and controls who 
had FISH after August 2014 [n= 4 and n=8 for cases and controls at diagnosis, and n=14 for cases at detection of del(17p)] when probe for 1q gain and del (1p) were introduced. BMPC 




3.4.4.2 Comparison of survival outcomes(table 13) 
 
Comparing survival outcomes from initial diagnosis, PFS in the acquired del (17p) and 
control groups were 23.0 months (95% CI, 20.2-27.8) and 30.1 months (95% CI, 26.0-
33.9) respectively (P=0.032).  The OS in the two groups were 68.2 months (95% CI, 
50.8-74.8) and 106.1 months (95% CI, 101.6-119.4) respectively (P<0.001). The 
results were also valid in subgroups based on prognostic factors except HRTs (Table 
13).  PFS in patients with de novo del(17p) was similar [21.2 months (95% CI, 17.8-
23.9); P=0.887] and OS trended towards being shorter [47.3 months (95% CI, 42.7-
55.9); P=0.063] when compared to the acquired del(17p) group. The comparison of 
PFS and OS for the three groups is shown in Fig 25. OS landmarked from detection 
of del(17p) for cases and a corresponding time point for controls were 18.1 months 
(95% CI, 11.9-25) and 56.2 months (95% CI, 44.4-79.7) respectively (P<0.001). 
 
 
Table 13. Sub-group analysis for overall survival from diagnosis in patients with acquired 
del(17p) and controls based on prognostic factors at diagnosis and therapy 
Subgroups Acquired del(17p) (n=76) 
Control patients 
(n=152) P* 
Age <65 (48 vs. 101) 72.3 (49.6-99.0) 106.1 (98.5-127.8) 0.002 
Age ≥65 (28 vs. 51) 58.2 (44.1-71.3) 105.9 (68.6-138.8) <0.001 
    
High-risk translocation (14 vs. 14) 56.8 (24.0-119.0) 98.3 (60.5-111.8) 0.419 
No high-risk translocation (62 vs. 138) 68.9 (50.8-74.8) 111.7 (103.4-129.3) <0.001 
    
ISS I/II (42 vs. 110) 71.3 (50.8-75.4) 106.1 (101.6-129.3) <0.001 
ISS III (14 vs. 26) 44.4 (13.8-103.1) 104.8 (60.7-111.8) 0.036 
    
Low LDH (44 vs. 116) 63.8 (44.6-99.0) 105.9 (98.5-119.4) 0.004 
High LDH (7 vs. 5) 55.5(23.2-86.4) 100.9 (80.6-NR) 0.011 
    
Low PC proliferative rate (31 vs. 84) 74.6 (58.3-99.0) 106.1 (98.3-137.8) 0.025 
High PC proliferative rate (14 vs. 24) 42.2 (24.0-103.1) 103.4 (67.1-NR) 0.031 
    
PI-containing induction (21 vs. 37) 34.5 (24.0-50.8) 104.8 (70.2-137.8) <0.001 
Others (55 vs. 115) 74.6 (63.8-96.5) 106.1 (98.5-127.8) 0.003 
*P for log-rank test for Kaplan Meier analysis; ISS indicates international staging system; LDH, Lactate 








3.4.4.3 Patient characteristics at detection of del(17p) 
 
The median time from diagnosis of MM to detection of del(17p) in the acquired del(17p) 
cohort was 35.6 months (range, 4.8-116.1). Patients had received a median of 2 (range, 
1-10) prior lines of therapy before detection of del(17p). Del(17p) was detected in 
median of 89% (range, 9-100) of PCs tested by FISH. Fifty seven (67.1%) and 33 
(43.4%) patients respectively were exposed to and refractory to a PI; 70 (92.1%) and 
57 (75.0%) patients respectively were exposed to and refractory to an IMiD (majority 
being lenalidomide and/or pomalidomide); and 60 (78.9%) and 25 (32.9%) patients 
respectively were exposed to and refractory to an alkylating agent. Thirty (39.5%) 
patients were PI and IMiD-refractory. 
 
 
3.4.4.4 Cytogenetics at acquisition of del17p(table 14) 
 
Seventy (86.8%) patients had del(17p13.1). Five (6.6%) patients had monosomy 17. 
One (1.3%) patient demonstrated both del(17p13.1) and monosomy 17. Four (5.3%) 
patients had relative loss of 17p. HRTs were present in 14 (18.4%) patients. Compared 
to initial FISH, proportion of patients with hyperdiploidy increased at detection of 
del(17p) (42.1% to 59.2%; P<0.001). A similar change was seen with monosomy 13 
(35.5% to 53.9%; P<0.001) while no change was seen with del(13q) (3.9% and 6.6%; 
P=0.187). Even though 4 (28.6%) patients at follow-up had 1q22 gain, none of these 


















Table 14. Cytogenetic abnormalities at diagnosis (cases and controls) and at acquisition of del (17p), n (%) 
High-risk chromosomal translocation 14 (18.4) 14 (9.2) 14 (18.4) 0.055 
t(4;14) 12 (15.8) 10 (6.6) 12 (15.8) 0.033 
t(6;14)† 0 (0) 0 (0) 0 (0) - 
t(11;14) 15 (19.7) 37 (24.3) 15 (19.7) 0.505 
t(14;16) 2 (2.6) 3 (2.0) 2 (2.6) 1.000 
t(14;20)† 0 (0) 1 (1.4) 0 (0) 1.000 
Hyperdiploidy (trisomy or tetrasomy involving ≥2 odd-numbered 
chromosomes) 
32 (42.1) 69 (45.4) 41 (53.9) 0.673 
Del (13q) and/or monosomy 13 30 (39.5) 67 (44.1) 45 (59.2) 0.570 
• Del (13q) 3 (3.9) 8 (5.3) 5 (6.6) 0.756 
• Monosomy 13 27 (35.5) 59 (38.8) 41 (53.9) 0.666 
(1q22) gain‡ 0 (0) 1 (12.5) 4 (28.6) 1.000 
Del (1p32)‡ 0 (0) 0 (0) 0 (0) - 
*P for Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables. †Calculation is limited to cases and controls who had 
FISH after May 2009 [n=37 and n=69 for cases and controls at diagnosis and n=68 for cases at detection of del(17p)] when probes for these abnormalities 
were introduced. ‡Calculation limited to cases and controls who had FISH after August 2014 [n= 4 and n=8 for cases and controls at diagnosis, and n=14 
for cases at detection of del(17p)] when probe for 1q gain and del (1p) were introduced. BMPC indicates bone marrow plasma cell; FISH, Interphase 
fluorescence in situ hybridization; ISS, International Staging System; and LDH, Lactate dehydrogenase. 
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3.4.4.5 Treatment after detection of del(17p) 
 
All patients received therapy after detection of del(17p). IMiD-based and PI-based 
regimens were used in 22 (28.9%) patients each and PI+IMiD-based regimen was 
used in 15 (19.7%) patients. Monoclonal antibodies were used in 4 (5.3%) patients. 
Seven (9.2%) patients proceeded directly to SCT without additional therapy and 6 
(7.9%) patients received other therapies. Overall, SCT was part of the next line of 
treatment in 14 (18.4%) patients (one of them underwent allogeneic SCT).  
 
 
3.4.4.6 Response to therapy after detection of del(17p) 
 
Among 67 patients who were evaluable for response, stringent complete response 
(sCR), CR, very good partial response (VGPR) and PR were attained in 3 (4.5%), 3 
(4.5%), 16 (23.9%) and 9 (13.4%) patients respectively. A minimal response was seen 
in 3 (4.5%) patients. Twenty (29.8%) patients showed stable disease while 13 (19.4%) 




















3.4.4.7 Survival after detection of del(17p)(Fig 26) 
 
 The median PFS from start of next line of therapy was 5.4 months (95% CI, 2.7-7.7). 







Fig 26: Survival outcomes in patients with acquired del(17p) -  The median OS was 18.1 








3.4.5 Predictors of survival after detection of del(17p) 
 
3.4.5.1 Factors affecting PFS after detection of del(17p)(Fig 27) 
 
To identify factors affecting PFS and OS from detection of del(17p), we used age ≥ 65 
vs. <65 years, serum creatinine >2 vs. ≤2 mg/dL, bone marrow PC percentage ≥50 vs. 
<50, ISS stage III vs. I or II, elevated vs. normal LDH, presence vs. absence of an HRT, 
presence vs. absence of monosomy 13, presence vs. absence of hyperdiploidy, high 
vs. low PC proliferative rate, prior PI and IMiD refractoriness and different proportions 
of PCs with del(17p) (20%, 30%, 40%, 50% and 60%) in the Cox proportional hazards 
model (Table 13).  
 
After univariable analysis, ISS stage III disease, high PC proliferative rate, PI and IMiD-
refractoriness and presence del(17p) in ≥30%, ≥40% and >50% PCs, had P<0.1 for 
predicting shorter PFS and were included in multivariable analysis. Using multivariable 
Cox proportional model with step-wise backward elimination, presence of del(17p) in 
≥40% PCs predicted shorter PFS with hazard ratio (HR) of 2.21 (95% CI, 1.21-4.01) 
(P=0.009). The median PFS in patients with del(17p) involving ≥40% PCs and <40% 
PCs were  3.5 months (95% CI, 1.9-5.7) and 11.3 months (95% CI, 4.4-15.6) 




































3.4.5.2 Factors affecting OS after detection of del(17p)(Fig 28) 
 
In a similar analysis, ISS III stage, elevated LDH, high PC proliferative rate and PI and 
IMiD-refractoriness were included in the multivariable model to determine predictors of 
shorter OS. A higher PC proliferative rate alone predicted shorter OS with HR of 2.28 
(95% CI, 1.31-3.96) (P=0.004). The median OS in patients with high PC proliferative 
rate at detection of del(17p) was 8.9 months (95% CI, 4.9-17.1) vs. 35.6 months (95% 


























3.4.5.3 Factors Predictive of acquisition of del17p (Table 15) 
 
To identify predictors at diagnosis of acquisition of del(17p), we compared patients with 
acquired del(17p) with controls in a case-control fashion and calculated OR. High LDH 
at baseline [OR- 3.69 (95% CI, 1.11-12.24)], presence of t(4;14) [OR- 2.66 (95% CI, 
1.09-6.48)] and presence of an HRT [OR- 2.23 (95% CI, 1.00-4.95)] predicted 
acquisition of del(17p). Age ≥65 years, ISS III stage, t(11;14), any trisomy/tetrasomy, 
hyperdiploidy, monosomy 13, bone marrow PC%, initial therapy, and exposure to high-
dose melphalan in first year and before acquiring del(17p) were not predictive 
 
Table15. Comparative analysis between patients with acquired del(17p) and controls for 
putative risk factors at diagnosis for acquiring del(17p). 
Presumed risk factor for acquiring del (17p) Odds ratio (95% CI) 
Age ≥65 years (28/76 vs. 51/152) 0.1.16 (0.65-2.05) 
ISS III stage (14/56 vs. 26/136) 1.41 (0.67-2.96) 
Elevated LDH (7/51 vs. 5/121) 3.69 (1.11-12.24) 
Bone marrow plasma cell % ≥50% (21/70 vs. 
62/150) 0.61 (0.33-1.11) 
High plasma cell proliferative rate (14/45 vs. 
22/106) 0.72 (0.78-3.79) 
High-risk translocations (14/76 vs. 14/152) 2.23 (1.00-4.95) 
t(4;14) (12/76 vs. 10/152) 2.66 (1.09-6.48) 
t(11;14) (15/76 vs. 37/152) 0.76 (0.39-1.50) 
Monosomy 13 (27/76 vs. 59/152) 0.86 (0.49-1.54) 
Any trisomy/tetrasomy (38/76 vs. 90/152) 0.69 (0.40-1.20) 
Hyperdiploidy (trisomy/tetrasomy of ≥2 odd-
numbered chromosomes) (32/76 vs. 69/152) 0.87 (0.50-1.53) 
PI-containing induction (21/76 vs. 37/152) 1.19 (0.64-2.22) 
Alkylating agent in induction (17/76 vs. 36/160) 1.00 (0.52-1.94) 
Autologous SCT with high dose melphalan 
within 1 year of diagnosis (and before 
detection of del(17p) for cases) (33/76 vs. 
82/152) 
0.65 (0.38-1.14) 
ISS indicates international staging system; LDH, Lactate dehydrogenase; PI, Proteasome 





Increasing evidence supports a significant impact of cytogenetic abnormalities 
affecting the treatment response and survival outcomes for MM patients. These 
abnormalities are classified as primary abnormalities which are common in MGUS 
stage and secondary abnormalities, that increase in frequency with more active 
disease.  The disease has 50% of patients with IgH translocations (non-hyperdiploid 
group), and the non-hyperdiploid abnormalities unique to the subclonal population of 
MMPC makes the disease biology complex and a clinical challenge for treatment. 
OS of patients with high-risk cytogenetic aberrations in MM has been shorter as 
previously noted.  
 
Several initial studies identified the additive prognostic significance of t(4;14) and 
del17p to conventional MM ISS staging system which is computed on patient’s 2 
microglobulin and albumin levels. These chromosomal aberrations favourably risk 
stratified MM patients into low[no del17p or t(4;14)], intermediate (neither low or high) 
and high(either or both of t(4;14), del17p) risk-groups[364, 365]. Palumbo et al. 
confirmed these findings in their report studying 3060 patient pooled data from 11 
trials with available ISS, LDH and cytogenetic abnormalities related data. Here, 
adding t(4;14) and del17p to standard ISS predicted for PFS and OS, in MM patients 
with five year OS rates of 82%, 62% and 40% in R-ISS(revised ISS with cytogenetic 
aberrations) stage I, II and III groups respectively. Importantly this prognostication 
system was valid irrespective of ASCT, novel agent or age of the patient[107]. 
 
Therapies targeting high-risk cytogenetic abnormalities are currently needed. t(4;14) 
occurs in about 15% of MM patients. Chng et al. showed that MM patients and cell 
lines with t(4;14) have a high centrosome index (CI) and overexpress aurora kinases 
and further patients with high CI have shorter PFS despite treatment with 
Bortezomib[366]. We studied the role of A1014907 in MM cell lines and patient cells 
to identify its role in Aurora kinase inhibition. The cell cycle inhibition secondary to 
Aurora kinase inhibition was validated by our; experiments however, we observed a 
dramatic difference in the sensitivity of t(4;14) containing MM cell lines when 
compared with the non-t(4;14) cell lines. This is unlikely to be explained merely by 
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aurora kinase inhibition. Chang H et al. previously demonstrated 75% FGFR3 
expression in t(4;14) MM patients[367]. We hypothesized a role of simultaneous 
inhibition of FGFR3 expression and aurora kinases in t(4;14) cell lines. Our results 
show that A1014907 inhibits aurora kinases and FGFR3. In cells lacking FGFR3 
expression, A1014907 caused cell cycle arrest in a majority of them but failed to 
induce marked apoptosis. In cells expressing wild type FGFR3 or those with 
activating mutations in FGFR3 (Y373C or G382D), A1014907 caused potent cell 
cycle arrest besides pronounced apoptosis.  
 
Furthermore, we dissected the FGFR3 mediated downstream pathways and showed 
clear evidence that FGFR3 inhibition by A1014907 resulted in down-regulation of 
both the PLCγ/PKC and Stat3 signalling pathways leading to apoptosis induction in 
these cell lines. Upregulation of pErk and pAkt in MM1S reflects upon the possible 
cause of drug resistance in the absence of FGFR3 expression. Importantly, 
A1014907 effectively induced cytotoxicity in FGFR3 expressing CLL cell lines, 
highlighting its broader application in other malignancies with high CI and FGFR3 
expression. Combination with Stat3 and Akt inhibitor would be useful in non-FGFR3 
expressing tumour systems.     
 
 We describe the outcomes of 310 del17p MM patients treated at Mayo Clinic, 
Rochester. This subset of patients lacks a definitive description of disease 
characteristics and associated features. A lack of specific studies with large patient 
cohorts accurately assessing patients with del17p has predominantly directed efforts 
to extrapolate results from more extensive MM trials or small cohort-based studies. 
Majority of patients presenting with high risk features received a PI-containing 
induction. Over 50%  had an SCT. PR was Seventy-six percent although lower in 
comparison to SR and high-risk translocation groups. In the del17p group, the 
median PFS and OS were 21 months and 47 months, respectively. The ISS stage, 
LDH level and simultaneous high-risk translocations predicted for OS. 
 
Low Hb, high LDH level and PC proliferation rate, were noted in the del17p cohort. 
Similar observations were made by Fonseca et al. in a smaller patient cohort. 
Compared to a previous report of 110 patients, we observe lesser del17p with ISS III 
disease in our patient sample(our cohort: 36% vs 45% in the study cohort) [368]. 
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There is a discrepancy noted in selection criteria for cut-off’s defining acceptable 
del17p %. The GMMG-HD4/HOVON65 trial used a 10% threshold for del17p and 
demonstrated PFS and OS adverse events with the lesser cut off; the IFM group 
used a higher 60% cut off for del17p assessment however they had  lesser number 
of purified PC’s in many samples (median % of 6% plasma cells)[141, 369]. t(4;14), 
trisomies, t(11;14) and chromosome 13 abnormalities are common in del17p patients 
as previously described[368]. 
 
In keeping with bortezomib’s role in improving outcomes of high-risk cytogenetics, 
majorly all patients with del17p and high-risk translocations in our study received a PI 
regimen based induction therapy[140, 141]. Combinations of PI and IMID were 
favoured in Del(17p) patients when compared to HRT-patients (39 vs 24%). 
Interestingly, PI-based induction did not predict for an improved PFS or OS in 
patients with del(17p) in our analysis. SCT  within a year was more likely pursued in 
del17p cohort although this approach did not ascertain an OS benefit in these 
patients. 
 
 Neben et al. showed an OS of 62% in MM patients treated with velcade doxorubicin 
and dexamethasone induction followed by HDT/ASCT and bortezomib maintenance. 
Otherwise, the inferior PFS and OS in the del17p patient has been previously 
reported[101, 125]. While the nature of the studies make direct comparisons difficult 
as simultaneous high-risk abnormalities might not be considered, it would be 
interesting to note the role of PI/IMID based maintenance. 
 
Similar PFS was seen in HRT and del17p patients. This could be due to similar 
induction therapy related effects in both subgroups. Shorter median OS after del17p 
acquisition suggests an increased relapse risk or disease becoming treatment 
refractory. There is a significant influence of concurrent genetic abnormalities for OS 
outcomes as noted in our study. The presence of simultaneous high-risk 
abnormalities with del17p portends a poor OS at 29.5 months compared to 51.4 
months and 79 months for Del17p alone and controls with high-risk translocation 
respectively. The PFS for Del17p cohort with simultaneous high-risk translocations in 
our cohort was 14.7 months which is comparable to the PFS of 17 months seen by 




Concurrent hyperdiploidy in del 17p cohort trended towards improved OS. Several 
previous studies demonstrate a similar adverse effect of cumulative high-risk 
cytogenetics with ameliorating role of trisomies[67, 111, 370]. Del17p is either R-ISS 
stage II or III based on other features[107]. It is noteworthy to consider restratification 
of R-ISS classification given the adverse outcomes of simultaneous del17p and high-
risk translocations as an independent category irrespective of other factors.  
 
Importantly, 21 patients with relative loss of 17p, have unclear significance in 
previous reports. Our results show similar poor survival for this cohort as compared 
to the del17p group and hence should be considered an adverse prognostic marker 
 
Our studies highlighted a lack of significant role PC clone with del17p when taken 
together with other adverse factors. Hence, If del17p is detectable beyond 
background detection rate, It should be considered significant for del17p and 
considered high risk. 
  
We next studied the natural history of 76 MM patients who acquired del17p after 
diagnosis while on treatment. The OS of this group was naturally shorter which we 
estimated at 18 months. These patients have been shown to do poorly in several 
studies with median PFS( ranging between 3.4-7.6 months)[297, 371]. Comparing 
the median OS, some The median OS in clinical trial patients of RRRM treated with 
bortezomib-based regimen was 11.5 months, which is shorter than the OS in our 
patients from the detection of del(17p)[372]. The eloquent trial showed favourable im-
provement of PFS in relapsed and/or refractory MM(RRMM) in patients with del17p 
and t(4;14) with a median survival of 26 months in elotuzumab, lenalidomide and 
dexamethasone group[373]. Although they considered del17p if any MMPC was 
positive for the same, the results underlie the poor prognosis in this subset of patients 
with RRMM. However, we are unable to ascertain, the timing of del17p in the trials. 
Interestingly,  in a recent trial of ixazomib or placebo, with lenalidomide and 
dexamethasone in RRMM, among patients with del(17p) in the two arms, PFS was 
21.4 and 9.7 months respectively, the PFS in patients with del(17p) being similar to 
those with standard-risk cytogenetics[374]. These results were in patients with 
del(17p) defined using ≥5% PCs with del(17p). When using cut-offs of 20% and 60%, 
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21.4 vs 6.7 months, and 15.7 vs 5.1 months respectively were obtained in the two 
groups. In our series, using cut-offs from 20 to 60%, PFS ranged from 5.3 to 3.5 
months, suggesting progressively decreasing PFS with an increase in the size of the 
PC clone. A cut-off of 40% predicted shorter PFS in multivariable analysis. However, 
the size of the PC clone with del(17p) was not a predictor of OS. This is similar to the 
results we observed in a series of patients with de novo del(17p). 
 
High PC proliferative rate at the detection of del(17p) predicted a shorter OS. PC 
proliferative rate is a prognostic factor in patients with PC disorders including MM and 
light chain amyloidoisis.[375-378] PC proliferative rate detects cells in S-phase and is 
a marker of active DNA synthesis by malignant PCs. Presence of high PC 
proliferative rate may represent further deregulation of cell cycle control in patients 
with del(17p).  
 
An important finding of our study is a high OR for acquired del17p when certain 
specific parameters including, high LDH at diagnosis and presence of HRTs, 
especially, t(4;14). High LDH is usually a marker of aggressivity in the context of 
cancer biology. In solid tumours including renal cell carcinoma, melanoma and 
prostate carcinoma, high LDH portends poor OS and is a marker of metastatic 
disease[379]. High LDH levels are usually found at diagnosis and are predictive of 
disease relapse in haematological malignancies[380]. In MM increased LDH predicts 
for aggressive disease forms and reduced survival post chemotherapy[381, 382]. 
Hence a high LDH at diagnosis is likely a marker of advancing disease. A previous 
sequential analysis of patients has shown that presence of HRTs at baseline is 
associated with detection of more copy number abnormalities on follow-up and this 
was postulated to be due to higher genomic instability in these patients.[383]. Also, 
the use of high-dose melphalan with autologous SCT was not associated with the 
acquisition of del(17p). This is contrary to a previous report which associated high-
dose melphalan and autologous SCT with the acquisition of high-risk abnormalities 
including del(17p) at relapse.[384] However, the risk factors we identified were 
present at baseline in only a few patients in the acquired del(17p) and control groups, 





The results of our study would likely require validation in prospective studies with all 
available data. Baseline LDH, anticipated FISH testing at specific time intervals, all 
treatment-related data including maintenance therapy, are some of the shortcomings 
of our study. Further given the retrospective nature of the data, patients lacked 
homogeneity of therapy within the same subgroups. Subclonal analysis of TP53 
which is predictive of poor outcome was not assessed[386]. Data on the 1q gain were 



































Targeted treatment approach has significant advantages in the treatment of cancers 
as compared to conventional chemotherapy. A1014907 showed significant FGFR3 
inhibition activity which could have a significant role in high-risk MM disease patients 
with this inherently activated pathway. There is a broader scope for A1014907 in 
cancer therapeutics as seen with our data on CLL patients with active FGFR3 
signalling. This has significant implications for an individualized therapeutic approach 
using molecular diagnostic tools such as gene expression profiling to identify patients 
with activated specific signalling pathways.  
 
Del17p is a poor prognosis chromosomal aberration in MM with poor OS outcomes. 
ISS III stage, high LDH and high-risk translocations predict for shorter OS in patients 
with del(17p).  
 
del17p patients showed increased association with t(4;14) and high-risk 
translocations, highlighting an important association of secondary translocations in 
MM. This would significantly impact response to treatment as noted in our study; 
hence the need for newer therapeutic targets with the ability to overcome the poor 
prognostic impact of high-risk translocations and del17p 
 
Some of our unpublished work using gene expression profiling(GEP) showed an 
increased association of del17p with Aurora kinase A expression. This is plausible 
given increased PCLI and hence replication rate as shown in our study. Exploiting 
multi-targeted agents impacting dysregulated cellular mechanisms are likely to 
induce more profound disease response with lesser generalized cytotoxicity.  
 
While we establish an increased association of t(4;14) and del17p, it would be 
noteworthy to see whether the subset of these patients who have an activated 
FGFR3 pathway tend to do better with targeted treatment such as A1014909 or it can 
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